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ABSTRACT 
Armed with the complete sequence of the human genome and an ever-increasing array of 
biological techniques, researchers continue to learn more about the genetic basis of 
diseases.  For two decades, scientists and physicians have been developing therapeutic 
strategies for treating many diseases at the genetic level, creating the field of “gene 
therapy.”  For those diseases caused by loss-of-function mutations in a specific gene, 
delivery of a wild-type copy of that gene to affected cells can reduce or eliminate the 
disease phenotype.  Viruses, having evolved to be extremely effective at delivering nucleic 
acids (i.e., their own genes for viral production) to cells, have been modified to include 
therapeutic genes of interest.  While such viral gene therapy vectors are the most efficient 
vectors developed, concerns about their safety and immunogenicity have prompted many to 
investigate non-viral vector alternatives.  Cationic polymers and lipids have emerged as 
leading non-viral vector materials.  Our laboratory has developed a class of cyclodextrin-
containing polycations (CDPs) that condense DNA into complexes that can be endocytosed 
by cells, achieve expression of their genetic payload in those cells, and may be modified to 
target particular cell types within an animal. 
In the past five years, scientists have discovered a new mechanism for the reduction of gene 
expression in mammalian cells via sequence-specific cleavage of a particular messenger 
RNA (mRNA); this phenomenon is known as RNA interference (RNAi).  Since RNAi is 
triggered by nucleic acids (small interfering RNA (siRNA) duplexes), I hypothesized that 
CDPs may be suitable vectors for the delivery of siRNA.  In my thesis work, the safety of 
synthetic siRNA duplexes is examined both in cultured cells and in vivo.  Using a number 
of different siRNA sequences, two different strains of mice, and three different methods of 
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administration, I fail to observe any cytokine (IL-12 or IFN-α) responses, morphological 
changes, or alterations in complete blood counts (CBCs) or liver enzyme levels. 
The ability of CDP to serve as a delivery vehicle for siRNA is also explored.  I demonstrate 
that CDP/siRNA complexes can be formed that are small enough to be endocytosed, can be 
modified to ensure stability in physiological fluid, and protect the siRNA payload from 
serum nuclease degradation.  Finally, down-regulation of specific target genes, including 
genes implicated in disease, is shown in vitro and in mice.   An endogenous reporter gene 
(luciferase) in the livers of transgenic mice is down-regulated by galactosylated 
CDP/siRNA formulations that target hepatocytes.  The level of a chimeric oncogene, EWS-
Fli1, is reduced by polyplex formulations in cultured Ewing’s sarcoma cells and by 
transferrin-targeted formulations in tumor-bearing mice; this in vivo down-regulation 
corresponds to an inhibition of tumor growth.  These results suggest that CDP-containing 
siRNA formulations have the potential for development into therapeutics. 
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CHAPTER 1: An Introduction to RNA Interference 
 
1.1 ABSTRACT 
There are numerous medical indications that could be treated by reducing the expression of 
one or more target genes, such as viral infection (genes required for viral replication) and 
cancer (oncogenes).  Scientists have developed some nucleic acid-based molecular 
therapeutics, such as antisense oligonucleotides and ribozymes, that can accomplish this 
down-regulation.  However, issues with potency, specificity, and delivery have hampered 
development of these molecules for more therapeutic applications.   In the past few years, a 
novel mechanism for down-regulation of genes in mammalian cells has been discovered.  
Triggered by double-stranded RNA and acting by sequence-specific cleavage of the 
messenger RNA (mRNA) gene product, this phenomenon is known as “RNA 
interference,” or RNAi.  Already having become the tool of choice for researchers to 
identify gene targets and elucidate function, RNAi has an exciting potential for therapeutic 
applications that is just starting to be realized.  This chapter contains a discussion of the 
current state of knowledge of RNAi, including comparisons to antisense technology, the 
mechanism of action, and highlights of therapeutic results. 
2 
1.2 ANTISENSE OLIGONUCLEOTIDES 
Prior to the discovery of RNAi and its still-emerging application as a therapeutic, the tool 
of choice for the down-regulation of a specific target gene was the antisense 
oligonucleotide.  The effector molecule, typically single-stranded DNA (ssDNA, which is 
more stable to nucleases than ssRNA), is designed to be complementary to the messenger 
RNA (mRNA) of the desired target gene such that it will anneal to the mRNA and prevent 
translation.  The specificity of this approach is based on Watson-Crick base pairing 
interactions, and the most effective knockdown using this technique is often observed with 
a an RNase-H dependent cleavage mechanism of mRNA targets. 
Despite their promise, the specificity of the biological effects observed by antisense 
molecules has fallen under question in recent years.  In order to minimize the non-
specificity and toxicity associated with antisense molecules that have been observed in 
vitro and in vivo, they have been chemically modified to improve their target binding 
affinity and to prevent nuclease degradation.  As one example, incorporation of an entirely 
phosphorothioate (P=S) backbone and incorporation of 2’-methyoxyethyl modifications on 
the terminal (5’ and 3’ ends) bases gives nuclease resistance and increased mRNA binding 
while permitting RNase-mediated degradation1-2.  Much longer studied than RNA 
inteference, there is already one antisense oligonucleotide product approved for local 
therapy of cytomegalovirus retinitis (Vitravene) and nearly twenty others in late-stage 
clinical trials and development targeting, among others, bcl-2, PKC-α, and DNA 
methyltransferase. 
Antisense oligonucleotides have not developed into ubiquitous molecular therapeutics as 
was initially hoped.  Despite the successes mentioned above, folding of target RNAs and/or 
3 
their association with specific proteins in the cell often prevent the antisense molecules 
from binding to their targets. This requires employment of relatively high doses in order to 
achieve a therapeutic effect; these high doses, as well as the consequently high toxicity that 
is sometimes observed, have made antisense molecules less than ideal for therapeutic 
product development.  As discussed below, the discovery of RNA interference, requiring 
double-stranded RNA, demonstrates greatly enhanced potency and thus is attracting a great 
deal of interest as a possible improvement upon/successor to antisense.  
4 
1.3 RNA INTERFERENCE  
1.3.1 Discovery of RNA interference 
The phenomenon of double-stranded RNA-(dsRNA-)induced gene silencing that we now 
call RNA interference (RNAi) emerged from studies dating back to the 1980s.  It was 
initially observed in plants that introduction of exogenous “transgenes” could alter the 
levels of expression of endogenous genes that possessed some amount of sequence 
homology; this was termed “homology-dependent gene silencing” (HDGS)3.  Further work 
suggested that HDGS was found in a wide variety of organisms4-5 and that it could be 
correlated to covalent modifications of genomic DNA, particularly methylation of cytosine 
residues6, which can lead to conversion to thymidine7.  Interestingly, the effect  of 
methylation was different depending on the region of the gene being methylated—
methylation of promoter sequences led to transcription silencing8-9 (“transcriptional gene 
silencing,” TGS), while methylation of the coding sequence corresponds to mRNA 
destabilization (“post-transcriptional gene silencing,” PTGS). 
It wasn’t until some investigations in worms (C. elegans) in the 1990s that RNA was 
shown to trigger gene silencing in an inheritable manner.  Both sense and antisense RNAs, 
when injected separately, were equally effective at silencing homologous target genes10. 
The seminal discovery following this was made by Fire and Mello, who demonstrated that 
the combination of sense and antisense RNAs (essentially dsRNA) together gave greater 
than ten times down-regulation than either RNA alone11.  It was this finding that led to the 
realization that RNA was responsible for the HDGS phenomena observed up to a decade 
earlier and sparked the cascade of research on RNAi in mammalian cells that continues to 
grow. 
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Initial in vitro investigations of RNAi showed that RNAi-induced silencing was realized 
via degradation of messenger RNA (mRNA)12.  An assembly of the dsRNA with a 
nuclease to form a “RNA-induced silencing complex” (RISC) was observed.  After extracts 
from RNAi-induced cells were shown to possess discrete ~25 nt RNAs homologous to the 
target gene, it was discovered shortly thereafter that these RNAs cofractionated with the 
RISC13-14.  A critical extension was made in cell-free systems by Zamore and co-workers 
who determined that cell extracts contained the ability to process dsRNA into 22-nt effector 
RNAs termed “small interfering RNAs” (siRNAs)15. 
Quickly, more became known about the details of RISC, both its protein and nucleic acid 
components.  Having a total size of ~500 kDa, the RISC was shown to contain the 
Argonaute-2 (Ago-2) protein and a family of RNase III proteins called Dicer16.  Dicer 
contains dual RNase III domains and dsRNA-binding motifs; it processes dsRNA into 
siRNAs and is recruited into the RISC by association between the PAZ domains found on 
both Dicer and Ago-217.  A detailed description of the current understanding of RISC 
formation is shown in Figure 1.1. 
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Figure 1.1 Mechanism of RISC formation. [Reproduced from Tomari and Zamore, 
200518] RLC: RISC-loading complex; Dcr-1: Dicer 1; Dcr-2: Dicer 2; Ago2: Argonaut 2. 
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Despite having developed this understanding of the key players and mechanism of RNAi, a 
significant hurdle remained to the development of RNAi as a research and therapeutic tool.  
The long dsRNA molecules that were cleaved into siRNA by Dicer are known to also 
interact with other cellular proteins that cause undesired, interferon-regulated responses 
(Fig. 1.2).  One of these proteins, the dsRNA-dependent protein kinase PKR, binds to and 
is activated by dsRNAs longer than 30 bp in length, leading to phosphorylation of eIF2α 
and global translational arrest19-20.  Another, 2’,5’-oligoadenylate synthetase, is activated by 
dsRNA and causes non-specific mRNA degradation via 2’,5’-oligoadenylate-activated 
ribonuclease L21. 
 
Figure 1.2 Mechanisms of immunogenicity of dsRNA. [Reproduced from Robbins and 
Rossi, 200522] 
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A critical breakthrough came when Elbashir and co-workers generated synthetic siRNAs 
(21-nt duplexes having symmetric 2-nt 3’ overhangs) and demonstrated that these could 
perform RNAi without needing cleavage by Dicer and without generating a PKR/interferon 
response23.  This finding opened the floodgates as the number of experimenters working 
with siRNA, and related small hairpin RNA (shRNA), has proliferated.  Today it is one of, 
if not the most, commonly used techniques to reduce levels of a particular gene to study its 
function or to elucidate a drug target. 
 
1.3.2 MicroRNAs (miRNAs) 
First discovered in C. elegans in 1993, small temporal RNAs (stRNAs), now known as 
microRNAs (miRNAs), are endogenous RNAs that accomplish targeted gene down-
regulation in a manner very similar to that of siRNA.  Sharing part of the mechanism of 
RNA interference described above, miRNAs have contributed significantly to the 
understanding of RNAi and its role in cellular and developmental biology. 
The first step of miRNA maturation is the nuclear cleavage of a primary miRNA transcript 
(pri-miRNA) to liberate a ~60 – 70 nt stem loop intermediate called the pre-miRNA 
(miRNA precursor)24.  This cleavage is performed by the nuclear enzyme Drosha, an 
RNase III endonuclease (just like Dicer), and generates a 5’ phosphate and 2-nt 3’ 
overhang on the stem-loop25.  Exportin-5 and Ran-GTP then transport the pre-miRNA from 
the nucleus to the cytoplasm.  In the cytoplasm, the second end of the mature miRNA is 
generated by Dicer, the same enzyme implicated in the generation of siRNA.  It is worth 
noting that the specificity of the initial cleavage (mediated by Drosha in the nucleus) 
determines the correct register of cleavage within the pre-miRNA and thus defines both 
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mature ends of the miRNA26.  This stands in contrast to the non-specific, progressive 
cleavages seen with Dicer.  Indeed, it has very recently been shown that small hairpin 
RNAs (shRNAs), 29-nt stem loop analogues of pri-miRNAs, also demonstrate a unique 
cleavage product that can be predicted27.  Having been cleaved by Dicer, the resulting 
miRNAs are recruited into the RNA-induced silencing complex (RISC) and proceed to 
silence homologous mRNA either via mRNA cleavage or translational repression.  A 
schematic comparison of miRNA and siRNA processing is shown in Figure 1.3. 
 
Figure 1.3 A comparison of microRNA (miRNA) and small interfering RNA (siRNA) 
processing. [Reproduced from Bartel, 200429] A. Biogenesis of plant miRNA. B. 
Biogenesis of metazoan miRNA. C. Biogenesis of animal siRNAs. 
 
Despite their functional similarity to siRNAs, miRNAs differ from siRNAs in regard to 
their origin, evolutionary conservation, and the types of genes they silence28.  Whereas 
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endogenous siRNAs are often derived from mRNAs, viruses, or transposons, miRNAs 
derive from loci that are unique for other recognized genes.  While endogenous siRNA 
sequences are rarely conserved, miRNA sequences are nearly always conserved among 
related organisms.  Finally, endogenous siRNAs “auto-silence,” i.e., they silence genes at 
the same locus, or very similar loci, from which they originate.  In contrast, miRNAs 
“hetero-silence” genes that are very different from their own origination. 
 
1.3.3 Chemical modification of synthetic siRNAs 
The seminal work with synthetic siRNA duplexes by Elbashir and colleagues demonstrated 
that 21-nt RNA (phosphodiester) duplexes with symmetric 2-nt, 3’ overhangs (either DNA 
or RNA) were sufficient to perform sequence-specific RNAi in mammalian cells23.  Since 
this initial discovery, a large body of work has been performed to investigate the tolerance 
for chemical modifications at all possible locations with these duplexes, including the 
termini and the backbones.  
A variety of modifications to the termini of siRNA duplexes, and their effect, if any, on 
their potency, have been examined.  It is clear that a 5’phosphate group is required on the 
antisense strand for mRNA cleavage; this requirement does not extend to the sense strand30-
31.  However, phosphorylation of a 5’ hydroxyl group on the antisense strand is performed 
by an intracellular kinase, so synthetic siRNA duplexes need not possess a 5’ phosphate 
group on the antisense strand.  As long as the 5’ phosphodiester linkage is maintained on 
the antisense strand, further modifications (e.g., incorporation of a fluorophore) to the 
antisense strand are tolerated30,32.  Many modifications to the 3’ end of antisenses strand are 
permitted without loss of potency (e.g., an inverted deoxy abasic residue33, puromycin or 
11 
biotin34, or a dideoxycytosine (ddC)31), but a couple of alternations have abrogated RNAi 
activity (2-hydroxyethylphosphate or 2’-O,4’-C-ethylene thymidine35).  While the TAT 
peptide or a TAT-derived oligocarbamate could be conjugated to the 3’ end of the antisense 
strand without compromising silencing activity36, fluorophore conjugation to this terminus 
(but not any others within the siRNA duplex) did abolish gene silencing32. 
Many experiments have been performed to understand the effect of interior modifications 
of siRNA duplexes and, in general, the results and conclusions are variable.  Two groups 
showed that the silencing activity of siRNA duplexes containing phosphorothioate (P=S) 
linkages (instead of phosphodiester (P=O)) was unaffected by this modification32,37.  
However, another group showed that P=S modification did indeed reduce siRNA activity38.  
Incorporation of a boranophosphonate (P=B) backbone within T7-synthesized duplexes 
(containing 5’ triphosphates) was better tolerated in the sense strand than antisense strand, 
and modification at the terminal regions of the strands only permitted retained activity of 
extended duration39.  Some sugar modifications, including 2’-deoxy-2’-fluoro (2’-F) and 
locked nucleic acid (LNA), have been shown to improve target binding affinity, and 2’-F 
siRNA shows enhanced serum stability but gives provides only comparable activity to 
unmodified duplexes in vivo40. 
  
1.3.4 Synthesis of siRNAs: in vitro transcription vs. chemical synthesis 
As an alternative to the more costly chemical synthesis of siRNA duplexes, many 
researchers have generated siRNA through in vitro transcription (IVT) methods.  This is 
generally done using bacteriophage promoters with (linearized) DNA templates, and the 
most common system employed (using the bacteriophage T7 RNA polymerase) produces 
12 
very potent siRNAs41-42.  However, it was demonstrated that T7-synthesized siRNAs are 
potent inducers of type I interferons (IFN-α and IFN-β) in numerous cell lines; single-
stranded oligos made in the same way generated similar responses43.  In fact, the presence 
of a 5’ triphosphate on these RNAs was implicated in this interferon response, leading to 
the development of an alternative IVT system that incorporates two 3’ adenosines43.  These 
adenosines prevent base-pairing with the initiating guanosines, thereby allowing the 
initiating 5’ nucleotides and triphosphates to be removed (by CIP and RNase T1).  This 
discovery should be considered when evaluating both the potency and immunogenicity of 
IVT siRNAs in previously-published and forthcoming reports. 
 
1.3.5 Evolutionary role of RNAi 
As we continue to learn more about the mechanism of RNAi and the similarity in 
processing between endogenous microRNAs (miRNAs) and exogenous dsRNA, the 
evolutionary purpose of the phenomenon of RNAi is a subject of much interest.  Indeed, at 
least three distinct roles of RNAi have been identified and are discussed briefly here: 
antiviral response, protection of the genome, and regulation of development. 
While dsRNA is not a participant in the central dogma of cell biology, the genetic material 
of numerous viruses is either directly packaged as dsRNA or its intracellular processing 
proceeds through a dsRNA intermediate.  It is logical, therefore, that cells have evolved a 
capacity to recognize dsRNA as foreign material and developed mechanisms for protection.  
Indeed, interferon responses and apoptosis mediated through dsRNA-mediated binding of 
cellular proteins, such as Toll-like receptor 3, protein kinase (PKR) or 2’,5’-oligoadenylate 
synthetase (2’-AS), are clear examples of this.  Research on plants has also shown that 
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genes implicated in RNAi are essential for viral protection; for example, Arabidoposis 
mutants in RNAi genes (sgs2 or sgs3) show hypersensitivity to infection by the 
cucumovirus44.  Perhaps RNAi evolution extends cellular protection to include shorter viral 
dsRNA triggers that complement the larger ones recognized by the other proteins 
mentioned above. 
All complex genomes contain unstable elements (transposons), often possessing repetitive 
sequences, whose motility can contribute to genomic mutagenesis.  There is evidence that 
RNAi-deficient worms (C. elegans) show increased rates of transposition45.  Also, 
sequencing of ~22-nt siRNAs has uncovered guide sequences corresponding to endogenous 
transposons that move via both RNA and DNA intermediates in Drosophila46.  These 
observations raise the possibility that RNAi has evolved to protect organisms from 
endogenous parasitic nucleic acids, such as transposons. 
A third role of RNAi is suggested to be within organism developmental control.  Mutations 
to Dicer or Argonaute-2 analogs in Arabidopsis led to stem cell defects causing 
developmental abnormalities or even embryo lethality47-48.  Worms that are defective in 
either of those genes, as well as the miRNA let-7, show similar phenotypes, including 
abnormal oocytes and the inability to fertilize eggs.  Thus the link between control of 
development timing and RNAi is clear and will likely continue to become better 
understood. 
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1.4 PRELIMINARY THERAPEUTIC APPLICATIONS OF RNAi 
A number of publications have come out that demonstrate the therapeutic potential of 
RNAi in animals, particularly mice.  Perhaps the most commonly examined therapeutic 
application of RNAi has been cancer, often owing to the specificity of the mutated gene 
target within cancer cells (and not others) and the relative ease of targeting these cells, 
which frequently over-express particular cell surface receptors.  Non-targeted DOTAP-
based liposomes have been used to deliver siRNA targeting the c-raf oncogene to human 
breast xenograft tumors in mice, resulting in 73% suppression of tumor growth49.  
Untargeted polyethylenimine-(PEI-)siRNA complexes reduced the growth of sub-
cutaneous SKOV-3 tumor xenografts in athymic mice due to specific HER-2 down-
regulation50.  Finally, the use of PEI-siRNA complexes that were PEGylated and targeted 
to integrins (at sites of neovasculature) via an RGD peptide reduced levels of EGFR and 
provided correspondingly reduced tumor angiogenesis and growth51. 
Many non-cancer therapeutic applications of siRNA have been demonstrated as well.  
Retro-orbital injection of PEI-formulated siRNA against influenza virus inhibits viral 
production in virus-infected mice52.  Systemic (intravenous) injection of polymer-bound 
siRNA against VEGF pathway genes reduces ocular angiogenesis53.  Electroporation of 
human livers cells with siRNA targeting the hepatic C genome (ssRNA) sharply reduced 
virus-specific protein expression and RNA synthesis54. 
These successful experimental results and others like them indicate that the therapeutic 
potential of RNAi is high and may be realized soon.  However, the known immunogenicity 
and/or toxicity of the non-viral vectors in these reports warrants investigation of alternative 
siRNA delivery systems that overcome these obstacles. 
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CHAPTER 2: Investigation of siRNA Immunogenicity 
 
 
2.1 ABSTRACT 
RNA interference (RNAi) has rapidly become the method of choice for the elucidation of 
gene function and the identification of drug targets.  However, some recent reports suggest 
that small interfering RNA (siRNA) duplexes that perform RNAi may induce an immune 
response in cells that take them up, most notably upregulating type I interferons (IFNs).  
Such immunogenicity would render therapeutic in vivo applications of siRNA unsafe for 
the patient and would preclude investigation of our polymeric system to deliver these 
duplexes.  However, the generality of the conclusions of these reports have been questioned 
for a variety of reasons, including the means of generation of the duplexes themselves, the 
lack of in vivo results to support these claims (only cell culture results were included), the 
use of a delivery vehicle for all samples (siRNA alone samples were not included), and the 
relatively high dose of siRNA employed.  Here, we carefully examine whether or not naked 
synthetic siRNA duplexes themselves induce a cytokine response, both in cultured cells 
and in mice.  Our results suggest that, even when administered in vivo by hydrodynamic 
delivery such that these naked siRNAs enter cells and are efficacious, synthetic siRNA 
duplexes do not induce a detectable immune response.  Our findings have very recently 
been confirmed by multiple other researchers.  From these results, we conclude that 
synthetic siRNA duplexes may indeed be safe for in vivo applications, and the ability of our 
polymeric system to deliver them merits exploration. 
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2.2 INTRODUCTION 
First discovered in plants two decades ago, the phenomenon of RNA interference (RNAi) 
has rapidly become the method of choice for the elucidation of gene function and the 
identification of drug targets in mammalian cells.  RNAi is achieved by double-stranded 
RNA (dsRNA) that triggers recognition and cleavage of the corresponding messenger RNA 
(mRNA) via the RNA-induced silencing complex (RISC) within the cytoplasm of cells.  
An intracellular enzyme (Dicer) cuts dsRNA into duplexes (21-23 nucleotoides (nt) in 
length) that are suitable for interaction with RISC.  While dsRNA larger than 21-23 nt in 
length may be appropriately Diced, it has been demonstrated in mammalian cells that 
dsRNA longer than 30 nt triggers a non-specific interferon pathway (through interaction 
with the protein kinase PKR1 and 2’,5’-oligoadenylate synthetase2) rather than RNAi.  In 
fact, small interfering RNA (siRNA) duplexes 21-23 nt in length can bypass Dicer and 
induce RNAi by incorporating within RISC directly, thereby eliminating the 
PKR/interferon response3,4.  Thus, although additional work has been done with both 
plasmids that express siRNAs and short hairpin RNAs (shRNAs) showing their suitability 
for RNAi, synthetic siRNA duplexes are preferred for most common, transient 
applications. 
While numerous reports have come out demonstrating the efficacy of siRNA duplexes to 
down-regulate a variety of targets in cultured cell lines, there have also been some reports 
of adverse effects of siRNA on cells that take them up.  Most notably, it has been claimed 
that siRNAs, while small enough to avoid interaction with PKR, activate an interferon 
response in a sequence-independent matter5-7.  If this were generally true, the potential of 
siRNA as a therapeutic would be sharply reduced, if not completely eliminated. 
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Careful inspection of these reports, however, suggests that all siRNA may not be 
immunogenic under all conditions.  For example, the siRNA examined was generated from 
a variety of sources, including chemical synthesis, processing of shRNA, and in vitro (T7) 
transcription.  Also, work was done in cultured cell models only (no in vivo results) and 
concentrations much higher than may be necessary for down-regulation (up to 100 nM) 
were employed.  Finally, all exposures to siRNA were performed in the presence of a 
delivery vector, either liposomal or viral in nature, which complicates interpretation of the 
results. 
Prior to exploration of whether our polymer-based system might be suitable for siRNA 
delivery, we decided to expand on the previous work investigating the interferon response 
to siRNA.  Since our delivery system has previously been shown to be non-toxic and well-
tolerated in mice8, we first investigated whether or not chemically synthesized siRNAs 
alone (without a delivery vector) elicit a cytokine response in cultured cells and in mice; for 
in vivo experiments, three different means of administration were compared.  Taken 
together, our results strongly suggest that chemically synthesized siRNAs do not elicit an 
immune response in mice, even when administered under conditions that permit them to be 
taken up by cells and perform detectable down-regulation of a target gene. 
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2.3 METHODS 
2.3.1 Nucleic acids 
Poly(I:C) was purchased from Amersham Biosciences.  siRNA duplexes against luciferase 
(“siGL3”), FAS (“siFAS”), c-Myc (“siCMYC”), and a non-targeting control duplex 
(“siCNTL”) were purchased from Dharmacon.  All came purified and pre-annealed by the 
manufacturer (“Option C”).  Sequences: 
 
siGL3: 
5’-CUUACGCUGAGUACUUCGAdTdT-3’ 
3’-dTdTGAAUGCGACUCAUGAAGCU-5’ 
 
siFAS: 
5’-GUGCAAGUGCAAACCAGACdTdT-3’ 
  3’-dTdTCACGUUCACGUUUGGUCUG-5’ 
 
siCMYC: 
5’-UCCCGCGACGAUGCCCCUCdTdT-3’ 
3’-dTdTAGGGCGCUGCUACGGGGAG-5’ 
 
siCNTL:   
5’-GACGUAAACGGCCACAAGUUC-3’ 
3’-CGCUGCAUUUGCCGGUGUUCA-5’ 
 
The luciferase-encoding plasmid (containing the firefly luciferase gene under the control of 
the human α1-antitrypsin promoter and the apolipoprotein E locus control region) was a 
generous gift of A. McCaffrey and M. Kay.  Where indicated, nucleic acids were pre-
incubated with 50 µg/mL RNase (Roche) at 37 oC for 30 min prior to use. 
2.3.2 RAW-264.7 studies 
RAW-264.7 cells were purchased from the American Type Culture Collection and cultured 
in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (heat-
inactivated) and 1x antibiotic-antimycotic (penicillin, streptomycin, and amphoterecin B).  
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5 x 106 cells were plated per well of a 24-well plate in medium containing 1.2% DMSO.  
After 24 h, mIFN-γ (Sigma) was added for 8 h to stimulate TLR3 expression.  
Lipopolysaccharide (LPS, Sigma, 1 µg/well), poly(I:C), or siRNA (siGL3) in indicated 
doses was added directly to appropriate wells for 24 h prior to harvesting the supernatant.  
IL-12(p40) levels were measured by ELISA (BD Biosciences) according to the 
manufacturer’s instructions. 
2.3.3 Mouse studies 
Female BALB/c and C57BL/6 mice (Jackson Laboratories) were treated according to the 
NIH Guidelines for Animal Care and as approved by the Caltech Institutional Animal Care 
and Use Committee.  All mice were 6-8 weeks of age at the time of injection.  siRNA was 
formulated in D5W (5% (50 mg/mL) glucose in water) such that a 10% (vol/wt) injection 
provided a 2.5 mg/kg dose, unless otherwise indicated.  Mouse tails were warmed with a 
heating pad prior to injection of a 0.2-mL (for “low-pressure”) or a 2-mL (for “high-
pressure”) volume (per 20-g mouse) over ~3–5 sec.  For co-injections of siRNA with 
plasmid DNA, 0.25 mg/kg DNA was delivered with 2.5 mg/kg of the appropriate siRNA.  
To determine luciferase levels, 0.2 mL of a 15 mg/mL solution of D-luciferin (Xenogen; in 
PBS) was injected intraperitoneally 10 min prior to imaging.  To measure plasma cytokine 
levels, blood was harvested from mice 2 h post-injection by cardiac puncture, and plasma 
was isolated using Microtainer tubes (Becton Dickinson).  [In preliminary experiments 
comparing the IL-12 response at 2 h, 6 h, and 24 h, post-injection, the maximum response 
was consistently observed at 2 h; therefore, data from the 2 h timepoint is used here.]  IL-
12(p40) and IFN-α levels (PBL Biomedical Laboratories) were measured by ELISA 
according to the manufacturer’s instructions.  To measure FAS mRNA levels, total RNA 
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was isolated from ~100 mg of liver tissue using the FastRNA Pro Green Kit (Qbiogene) 
and FastPrep Instrument (Qbiogene) for 40 sec at a speed setting of 6.0.   
1 µg total RNA was first digested with amplification grade DNase I (Invitrogen) and then 
reverse transcribed into double-stranded cDNA using oligo-dT and Superscript II 
(Invitrogen) following the manufacturer’s instructions.  PCR primers were designed with 
MacVector 7.0 (Accelrys). The primer sequences are: 
 
FAS (sense): 5'-GCAAACCAGACTTCTACTGCGATTC-3' 
FAS (antisense): 5'-CCTTTTCCAGCACTTTCTTTTCCG-3' 
 
For each PCR reaction, 1/40 (1 µL) of the cDNA reaction was amplified in a 25 µL 
reaction volume containing 0.5 µM of each primer and QuantiTect SYBR Green master 
mix (Qiagen). The real time quantitative PCR was performed and analyzed on SmartCycler 
(Cepheid). Standard curves were constructed by four serial 10-fold dilutions of cDNA 
starting from 1/20 (2 µL) of the cDNA reaction. Initial PCR conditions were 95 oC for 900 
s; followed by 40 cycles of 95 oC for 15 s, 55 oC for 30 s, and 72 oC for 30 s; then a final 
denaturing stage of gradual increasing temperature from 60 oC to 95 oC. The denaturing 
stage is used to generate the melting curve of PCR products, which correlate with the size 
and GC content of the PCR product. A parallel internal control (β-actin) was amplified at 
an annealing temperature of 60 oC. All PCR products were analyzed on a 1% (wt/vol) 
agarose gel and a single band corresponding to the desired PCR product was observed in all 
reactions except negative controls. The reproducibility of the quantitative measurement of 
each sample was evaluated by at least three PCR measurements.  The expression level of 
target gene was normalized to internal β-actin, and the mean and standard deviation of the 
target/β-actin ratios were calculated for sample-to-sample comparison.   
26 
2.4 RESULTS 
2.4.1 Naked synthetic siRNA fails to induce a cytokine response in cultured cells 
Poly(inosinic acid:cytidylic acid) (poly(I:C)), an analog of RNA, was included in these 
studies as a positive control for cytokine responses.  In order to generate a sample of 
digested poly(I:C) for comparison with intact material, poly(I:C) was incubated with 
various concentrations of RNase and electrophoresed on an agarose gel (Fig. 2.1). 
 
 
Figure 2.1 RNase degradation of poly(I:C). 1 µg poly(I:C) was incubated with RNase (at 
concentrations from 0–50 µg/mL) at 37 oC for 30 min, then electrophoresed on a 1% 
(wt/vol) agarose gel.  A complete absence of nucleic acid signal was seen for all RNase 
concentrations of 50 µg/mL and higher. 
 
Poly(I:C) is clearly very polydisperse, generating a broad smear even without exposure to 
RNase.  As the concentration of RNase is increased, the poly(I:C) migrates further, 
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consistent with it being degraded into smaller fragments.  For the highest RNase 
cconcentrations employed, no signal is visible on the gel, suggesting that the poly(I:C) has 
been completely degraded.  This result suggests that the highest RNase concentration used 
(50 µg/mL) is satisfactory to induce total degradation of poly(I:C) under these conditions, 
and it will be used for subsequent experimental work. 
We compared the effect of naked poly(I:C) and siRNA on cultured RAW-264.7 cells, a 
mouse monocyte/macrophage line that can be induced to secrete cytokines or express an 
NFκB-dependent reporter gene upon stimulation with poly(I:C).   We exposed RAW-264.7 
cells to various doses of intact poly(I:C), RNase-treated poly(I:C), or a synthetic siRNA 
duplex against luciferase (siGL3) for 24 h and measured levels of secreted IL-12(p40) in 
cell supernatants by enzyme-linked immunosorbent assay (ELISA) (Figure 2.2). 
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Figure 2.2 Poly(I:C), but not synthetic siRNA, induces IL-12 secretion by RAW-264.7 
cells.  IL-12(p40) levels in cell culture supernatants were measured upon 24 h exposure to 
the indicated nucleic acids and doses. The average of three replicate treatments is presented 
and error bars represent one standard deviation.  Lipopolysaccharide (LPS), which is 
known to induce a strong IL-12 response through interaction with Toll-like receptor 49, was 
used as a positive control for the detection of IL-12 in the assay.  [** denotes P < 0.005, # 
denotes P < 0.30] 
 
At all three doses examined (3 µg, 10 µg, and 30 µg), poly(I:C) invoked a clear IL-12 
response.  In contrast, synthetic siRNA failed to induce a measureable IL-12 response at 
any dose.  Pre-treatment of poly(I:C) with RNase completed abrogated the IL-12 response. 
2.4.2 Naked synthetic siRNA fails to induce a cytokine response in mice 
The effect of siRNA on IL-12 secretion was further examined in female BALB/c mice.  
Administrations of synthetic siRNA duplexes or poly(I:C) were performed as 
intraperitoneal (IP) injections or via the tail vein using either ‘low-pressure’ (LPTV, 1% 
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vol/wt) or ‘high-pressure’ (HPTV, 10% vol/wt) methods10-12.  Blood was collected 2 h after 
injection, plasma was isolated, and IL-12(p40) levels were examined by ELISA (Fig. 2.3). 
 
Figure 2.3 Poly(I:C), but not synthetic siRNA, induces IL-12 secretion in mice.  (a) 
Plasma IL-12 levels in female BALB/c mice.  2.5 mg/kg (unless otherwise indicated) of 
nucleic acid was injected by high-pressure (10% vol/wt). and plasma was collected 2 h 
post-injection. The average of three replicate mice is presented. and error bars represent 
one standard deviation. (b) Effect of various types of administration. Mice received 2.5 
mg/kg nucleic acid either intraperitoneally (IP) or through the tail vein via low-pressure 
(1% vol/wt, LPTV) or high-pressure (10% vol/wt, HPTV).  The average of three replicate 
mice is presented. and error bars represent one standard deviation. [** denotes P < 0.005] 
 
ELISA analyses of plasma IL-12 levels show, for each of the three different injection types, 
a strong induction by poly(I:C) that is absent with either a synthetic siRNA against FAS, c-
MYC, or luciferase (siFAS, siCMYC, siGL3), or RNase-treated poly(I:C), even when the 
siFAS dose is increased up to threefold. 
In addition to determining IL-12 concentrations, these experiments allow us to test for 
interferon responses.  The plasma levels of IFN-α in BALB/c mice exposed to siRNA 
(siFAS, siGL3, or siCMYC) or poly(I:C) were measured by ELISA (Fig. 2.4). 
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Figure 2.4 IFN-α induction in mice. 2.5 mg/kg of indicated nucleic acids were injected 
either intraperitoneally (IP) or through the tail vein via low-pressure (1% vol/wt, LPTV) or 
high-pressure (10% vol/wt, HPTV).  Plasma was collected 2 h post-injection, and IFN-α 
levels were determined by ELISA. The average of three replicate mice is presented, and 
error bars represent one standard deviation.  [* denotes P < 0.005, # denotes P < 0.025 vs. 
all other groups of same injection type] 
 
As was observed with IL-12, each siRNA failed to elicit an IFN-α response whereas 
poly(I:C) induced a strong response that was eliminated by pre-treatment with RNase. 
Further, injected synthetic siRNAs (siFAS and siCMYC) failed to induce any significant 
changes in critical blood chemistry or liver enzyme levels except for the cases where the 
HPTV method of injection is used (Fig. 2.5). 
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Figure 2.5 Synthetic siRNA does not alter mouse CBC or liver enzyme levels. (a) 
Alanine aminotransferase (ALT). (b) Alkaline phosphatase (ALKP).  (c) Platelets (PLTs). 
(d) White blood cells (WBCs).  For all panels, mice were injected with 5% (wt/vol) glucose 
in water (D5W) or 2.5 mg/kg indicated nucleic acids (in D5W) either intraperitoneally (IP) 
or through the tail vein via low-pressure (1% vol/wt, LPTV) or high-pressure (10% vol/wt, 
HPTV).  Blood was collected 2 h post-injection.  Whole blood was used to determine PLT 
and WBC levels, while plasma was isolated and used to determine ALT and ALKP levels.  
The average of three replicate mice is presented, and error bars represent one standard 
deviation. 
 
Finally, since there is the possibility that the PKR response in BALB/c mice may be 
compromised relative to other mouse strains13, some of the cytokine investigation 
experiments (originally performed with BALB/c mice) were reproduced in C57BL/6 mice, 
which are fully immunocompetent.  The results show that the effects observed are 
consistent within these two strains (Fig. 2.6). 
a
10
100
1,000
10,000
100,000
D5W Poly(I:C) siFAS siCMYC Uninjected
[A
LT
] (
U
/L
)
IP
LPTV
HPTV
b
0
50
100
150
200
250
D5W Poly(I:C) siFAS siCMYC Uninjected
[A
LK
P]
 (U
/L
)
IP
LPTV
HPTV
c
0
100
200
300
400
500
600
700
D5W Poly(I:C) siFAS Uninjected
[P
LT
s]
 (*
10
^3
/ µL
)
IP
LPTV
HPTV
d
0
5
10
15
D5W Poly(I:C) siFAS Uninjected
[W
B
C
s]
 (*
10
^3
/ µL
)
IP
LPTV
HPTV
32 
a 
500
600
700
800
900
1,000
D5W, HPTV siGL3, HPTV Poly(I:C), HPTV
[IL
-1
2(
p4
0)
] (
pg
/m
L)
b
0
200
400
600
800
D5W, HPTV siGL3, HPTV Poly(I:C), HPTV
[IF
N
- α]
 (p
g/
m
L)
 
 
Figure 2.6 Lack of IL-12 and IFN-α induction by siRNA in C57BL/6 mice. (a) Plasma 
IL-12(p40) and (b) IFN-α levels in female C57BL/6 mice. 2.5 mg/kg of nucleic acid was 
injected by high-pressure (10% vol/wt), and plasma was collected 2 h post-injection.  The 
average of three replicate mice is presented, and error bars represent one standard 
deviation. [* denotes P < 0.005 vs. all other treatment groups] 
 
 
2.4.3. Synthetic siRNA achieves sequence-specific gene knockdown in cultured cells 
While these results support the hypothesis that naked, synthetic siRNA duplexes do not 
induce an immune response in mice, further experimentation to verify nucleic acid stability 
and intracellular localization in the mice is necessary.  A synthetic siRNA duplex (siCNTL) 
was exposed to active mouse serum for up to 8 h and then examined for degradation via 
agarose gel electrophoresis (Fig. 2.7). 
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Figure 2.7 Degradation kinetics of synthetic siRNA in mouse serum. 40 pmol siCNTL 
was incubated in 20 µL mouse serum (active) at 37 oC for indicated times before being 
electrophoresed on a 15% (wt/vol) TBE gel. 
 
This result indicates that some of the siRNA is still intact after exposure to serum for 2 h, 
which is the timeframe at which an IL-12 response was investigated in mice (see Fig. 2.3). 
Further, siRNA duplexes have been shown to achieve down-regulation of genes for several 
days in cultured cells14.  When synthetic siRNA targeting luciferase (siGL3) is co-delivered 
with a luciferase-encoding plasmid (pGL3CV) to RAW-264.7 cells, sequence-specific 
down-regulation is observed 2 d post-transfection (Fig. 2.8). 
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Figure 2.8. Sequence-specific target down-regulation by siRNA in RAW-264.7 cells.  
Co-lipofection of siRNA with pGL3CV in RAW-264.7 cells achieves sequence-specific 
luciferase down-regulation.  Cultured RAW-264.7 cells were exposed to lipoplexes 
(containing Lipofectamine, made according to the manufacturer’s instructions) containing 
1 mg DNA and 20 nM siRNA (where indicated) for 4 h and then lysed at 48 h for 
measurement of luciferase and total protein levels.  The average of three replicate 
treatments is present as the ratio of luciferase level (RLU; relative light units) to total 
protein level (mg protein) for each sample.  Data are normalized to the average value for 
Lipofectamine/pGL3CV samples (no siRNA); this value (“100%”) is equal to 7.51 x 106 
RLU/(mg protein).  Error bars represent one standard deviation.  [* denotes P < 0.05 vs. all 
other treatment groups] 
 
 
2.4.4 Synthetic siRNA achieves sequence-specific gene knockdown in mice 
Additionally, we injected BALB/c mice with a luciferase-containing plasmid (encoding the 
firefly luciferase gene under the control of the liver-specific hAAT promoter with ApoE 
HCR enchancer, pApoEHCRLuc) alone or co-injected this plasmid with siRNA that 
contains the appropriate sequence to perform luciferase down-regulation (siGL3) or an 
unrelated sequence (siCNTL); all injections were HPTV.  The in vivo luciferase expression 
was followed for two weeks after injection by live whole-animal bioluminescence 
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imaging14-15.  A representative image containing one mouse from each of the three 
treatment groups 2 d post-injection is shown in Figure 2.9. 
 
 
Figure 2.9. Efficacy of synthetic siRNA in mice. In vivo whole-body imaging of female 
BALB/c mice injected by HPTV with luciferase-encoding plasmid alone (left) or with 
siRNA targeting luciferase (siGL3, center) or non-targeting control siRNA (siCNTL, right).  
These mice were imaged 2 d post-injection and 10 min after IP administration of D-
luciferin (for visualization). Scale bar has units of [photons/s/cm2/sr].  Sequence-specific 
reduction in luciferase signal is seen for the siGL3-treated mouse (center). 
 
The cumulative signal from each mouse was quantified at each time point, and the results 
are plotted in Figure 2.10. 
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Figure 2.10. Synthetic siRNA accomplishes sequence-specific RNAi of an exogenous 
target in mice. (a) BALB/c mice were imaged over two weeks post-injection and total 
luciferase signals were integrated, quantified, and normalized to mice that received pDNA 
only at each time point.  The average of three or more replicate mice is presented, and error 
bars represent one standard deviation.  [* denotes P < 0.005 at t=2 d, # denotes P < 0.025 at 
t=4 d, @ denotes P < 0.05 at t=6,9 d, ^ denotes P < 0.1 at t=13 d.  The “pDNA + siCNTL” 
group was not statistically different from mice that received pDNA only at these levels of 
significance for any of the timepoints examined.] (b) Raw (unnormalized) results from 
mice presented in (a). 
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Mice co-injected with the luciferase-targeting siRNA display a significant (P < 0.1 or better 
for all time points) down-regulation of luciferase expression that is not observed with the 
control siRNA.  The sequence-specific RNAi demonstrates that intact siRNA do reach 
intracellular targets and are functional in vivo at the conditions of our studies. 
A second efficacy experiment in mice showed that HPTV injection of siFAS reduces the 
level of FAS mRNA in mouse liver (Fig. 2.11). 
 
Figure 2.11 Synthetic siRNA accomplishes sequence-specific RNAi of an endogenous 
target in mice. BALB/c mice were injected with siFAS by HPTV or LPTV and sacrificed 
24 h post-injection.  FAS mRNA levels were quantified and normalized to β-actin by RT-
PCR.  The average of three replicate mice is presented, and error bars represent one 
standard deviation.  [* denotes P < 0.1] 
 
Both of these experiments demonstrate that, at least when delivered under these conditions, 
synthetic siRNA can be efficacious in vivo.  Thus the HPTV method of administering 
siRNA used here for examination of immunogenicity also provides for cellular uptake and 
gene down-regulation in the livers of mice14,16-17.  Given the stability and efficacy of 
multiple siRNAs, the lack of IL-12 and IFN-α expression obtained in mice suggests that 
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synthetic siRNAs used in this study do not elicit an observable immune response when 
administered naked by LPTV, HPTV, or IP methods in the amounts used here. 
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2.5 DISCUSSION 
Because small interfering RNA (siRNA) has shown impressive efficacy for down-
regulation of a target mRNA in a number of different cell lines and in vivo models, it has 
tremendous potential for development into a therapeutic.  However, some published reports 
have linked siRNA with off-target gene down-regulation and immunogenicity.  The 
objective of the work in this chapter is to determine whether or not synthetic siRNA 
duplexes are indeed immunostimulatory, both in cultured cells and in mice, prior to 
investigation of our polymeric system to deliver them. 
In cultured cells, there are reports of non-specific gene target effects that include off-target 
gene suppression and upregulation of type I interferons (IFNs)5-7,18-19.  Hypotheses for the 
mechanism belying this IFN response include recognition of the siRNA by Toll-like 
receptors 3 (TLR3) and 9 (TLR9) and/or induction of protein kinase PKR pathways.  When 
we applied naked synthetic siRNA to cultured cells known to be responsive to the 
downstream target of TLR3 and TLR9 signaling, the transcription factor NFκB, we failed 
to observe a cytokine response.  PKR is known to recognize dsRNA molecules of at least 
~30 bp in length1; the synthetic duplexes we examined here should all be too small to 
trigger an PKR response.  The cytokine response induced by poly(inosinic acid:cytidylic 
acid) (poly(I:C)), a large analog of RNA that is known to elicit an immune response in 
mice20-21, could be eliminated by pre-treatment with RNase.   
It is known that TLR3 is located both on the cell surface and intracellularly in human 
fibroblasts but remains intracellular in others, such as monocyte-derived immature 
dendritic cells22.  CpG-containing oligonucleotide/TLR9 interactions require internalization 
of the nucleic acid with TLR9-bearing cells23.  Thus, proof of nucleic acid stability and 
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intracellular localization in the mice are necessary.  We showed that ~50% of synthetic 
siRNA remains intact upon exposure to active mouse serum of 2 h.  This suggests that the 
lack of plasma cytokine (IL-12, IFN-α) responses seen in mice 2 h after injection with 
siRNA is truly the result of intact siRNA failing to trigger any response.  Further, in 
showing down-regulation of both exogenous (luciferase) and endogenous (FAS) targets 
after injection of synthetic siRNA in mice, we demonstrate the efficacy of these duplexes in 
vivo under our experimental conditions.  The down-regulation of FAS observed upon ‘high-
pressure’ tail vein (HPTV) injection was not seen upon ‘low-pressure’ injection (LPTV) of 
the same siRNA at the same dose, consistent with previous observations that high-pressure 
is required to achieve down-regulation of a target gene by naked siRNA in mice, even if the 
siRNA is chemically stabilized14. 
There is the possibility that the PKR response in BALB/c mice may be compromised 
relative to other mouse strains13.  Researchers have shown IL-12 responses to poly(I:C) in 
vitro with RAW-264.7 cells and in serum after IP injection in C57BL/6 mice like those 
shown here with the same cell line and BALB/c mice24.  We reproduced some of our 
experiments performed with the BALB/c mice in C57BL/6 mice, and the results show that 
the effects observed are consistent within those two strains. 
In conclusion, we examined the response of mice to naked siRNAs.  Plasma IL-12 and 
IFN-α levels that were observed in mice by injection of poly(I:C) (used as a positive 
control) were not obtained with siRNA.  Pre-digestion of poly(I:C) with RNase abrogated 
these responses.  Co-injection of siRNA and a luciferase-expressing plasmid into mice 
followed by in vivo whole-animal imaging confirms the uptake and sequence-specific 
function of injected synthetic siRNA.  HPTV injection of siRNA alone was also shown to 
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down-regulate an endogenous target gene (FAS) in mice.  Taken together, the results 
contained within this chapter suggest that synthetic siRNAs are well tolerated in mice and 
that it is indeed possible for siRNAs to down-regulate targets in vivo without stimulating an 
interferon response. 
Finally, very recently, the lack of immunogenicity seen here with naked synthetic 
siRNAs has been confirmed by multiple other researchers25-26, further strengthening the 
claim made here that synthetic siRNAs may be safe and efficacious for applications in 
animals.  There have been additional reports that particular motifs within siRNA 
duplexes endow them with sequence-specific immunogenicity25-28.  This issue, in the 
context of our polymeric delivery system, will be discussed in more detail in Chapter 4. 
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CHAPTER 3: Creation and Characterization of CDP/siRNA Complexes 
 
3.1 ABSTRACT 
In Chapter 2 the safety (non-immunogenicity) of synthetic small interfering RNA (siRNA) 
duplexes, both in cultured cells and in mice, was demonstrated.  Here the interaction of 
siRNA with a cyclodextrin-containing polycation (CDP) into complexes suitable for 
delivery to cells is investigated.    When added to nucleic acids, either siRNA or plasmid 
DNA (pDNA), CDP condenses them into small polymer-siRNA or polymer-pDNA 
complexes (“polyplexes”) that have ~50-100 nm in diameter.  Complexation with CDP 
endows siRNA with protection from nucleases and permits high levels of uptake by 
recipient cells.  These polyplexes can be stabilized by incorporation of a neutral polymer, 
poly(ethylene glycol) (PEG), to which a ligand, such as lactose or transferrin, can be 
tethered for targeting of particular cell type(s).  These CDP/siRNA polyplexes are excellent 
candidates to achieve RNA interference (RNAi) of a desired target gene. 
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3.2 INTRODUCTION 
The synthesis and characterization of cyclodextrin-containing polycations (CDPs), the first 
polycations designed specifically for the delivery of DNA, have been described1.  
Systematic investigations of modifications in the presence and type of sugar and the type of 
and spacing between charge centers have led to a thorough understanding of the effects of 
these parameters on the gene delivery efficiency and toxicity of polymer-DNA complexes 
(“polyplexes”)2-4.  From these and other studies5, an amine-terminated, β-cyclodextrin- (β-
CD-)containing polymer possessing cationic amidine groups separated by six methylene 
groups emerged as a leading candidate for further development (Fig. 3.1a). 
 
Figure 3.1. Structures of amine- and imidazole-terminated β-cyclodextrin-containing 
polycations. (a) Amine-terminated polycation. (b) Imidazole-terminated polycation. 
 
While transfection with polyplexes made with this amine-terminated polymer generated 
levels of gene expression in cultured cells comparable to that seen with the best 
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commercially-available polycation and lipid reagents1,6, microscopic analysis of transfected 
cells suggested that the majority of intracellular polyplexes were sequestered within 
endosomal vesicles6-7.  These vesicles are known to acidify within the cell and ultimately 
fuse with lysosomes, leading to degradation of intravesicular contents.  Modification of 
polymer termini to contain imidazole (Im) moieties (Fig. 3.1b), which are known to act as 
a buffer within the pH range of vesicular acidification, leads to increased gene expression 
and the observation of unpackaging polyplexes within transfected cells (Fig. 3.2).  
 
Figure 3.2. Imidazole-modification of CDP increases intracellular unpackaging of 
polyplexes. Cultured BHK (baby hamster kidney) cells were exposed to DNA-containing 
polyplexes made with either amine-terminated (a, c, d) or imidazole-terminated (b, e, f) 
CDP and examined by transmission electron microscopy (TEM).  In (a) and (b), shortly 
after uptake, polyplex-containing vesicles are at relatively neutral pH and are located close 
to the plasma membrane.  In (c)-(f), after additional intracellular trafficking, vesicles have 
acidified and have translocated to the perinuclear region.  Unpacking of polyplexes made 
with an imidazole-terminated CDP (e, f) is observed but not for those with amine-
terminated CDP (c, d).  [These images adopted from Mishra et al., 20047]  
 
While they are potent gene delivery systems in cultured cells, these CDP-containing 
polyplexes readily aggregate at physiological conditions, owing to their positively-charged 
colloidal nature8.  This problem of polyplex aggregation is most commonly overcome by 
covalent modification of polyplexes with a neutral polymer, such as poly(ethylene glycol) 
(PEG).  While it is possible to perform this covalent PEGylation and not disrupt 
polyplexes9, others have reported that this modification alters polyplex morphologies10 or 
48 
even prevents DNA condensation11; similar difficulties were observed with covalently 
PEGylated CDP8. 
However, the unique structure of β-CD allows for a novel approach to the PEGylation of 
CDP-containing polyplexes.  PEG is tethered to a small molecule, adamantane (AD), that is 
known to form strong, non-covalent inclusion complexes with β-CD12 (Fig 3.3a).  Addition 
of AD-PEG conjugates to CDP and the resulting inclusion complex formation permits the 
introduction of PEG at sites allosteric to those involved in nucleic acid binding (Fig. 3.3b).  
Indeed, unlike their unPEGylated counterparts, CDP-containing polyplexes modified with 
AD-PEG retain their as-formulated size when exposed to salt8 (Fig. 3.3c). 
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Figure 3.3. Modification of CDP/DNA polyplexes with AD-PEG confers salt stability. 
(a) Adamantane (AD) interacts strongly and non-covalently with β-cyclodextrin (β-CD) 
through inclusion complex formation. (b) Polyplexes prepared with a β-CD-containing 
polycation (CDP) are modified with poly(ethylene glycol) (PEG) by addition of an AD-
PEG conjugate. (c) The sizes of CDP/DNA polyplexes, PEGylated vs. unPEGylated, are 
measured in salt-free and salt-containing media by dynamic light scattering (DLS).  
Measurements were made in water for 30-sec periods over 2 min, then 0.11 volumes of 
phosphate-buffer saline (PBS) were added to bring the solution to a 1x (150 mM) final 
concentration.  Measurements were continued for an additional 2.5 min.  While a steady 
increase in size was seen for unPEGylated polyplexes after the addition of salt, the size of 
PEGylated polyplexes remained stable. 
 
CDP-containing polyplexes can be further modified to incorporate a targeting ligand to 
direct their selective uptake by particular cell types.  For example, transferrin (Tf) can be 
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introduced through synthesis of an AD-PEG-Tf conjugate; this conjugate had been shown 
to enhance polyplex uptake by cells that express high levels of the cell-surface transferrin 
receptor (TfR)13-14. 
While much work has already been done to better understand this CDP system, there still 
remain a number of unanswered questions regarding the exact composition and nature of 
CDP-containing polyplexes.  The amount and effect of unbound (i.e., not within 
polyplexes) material within polyplex formulations remain heretofore undetermined.  
Quantification of AD-PEG binding to polyplexes and its effect on cellular uptake warrant 
investigation.  Further, all of the developmental work discussed above was done in the 
context of DNA, almost exclusively with relatively large (~3-10 kbp) plasmids.  It remains 
to be determined if polyplexes can be prepared with small interfering RNA (siRNA) 
duplexes and, if so, how the polyplex properties might be affected.  All of these issues are 
addressed in Chapter 3. 
A gel retardation assay is employed to demonstrate that an equivalent amount of imidazole-
terminated polymer is required to bind the same mass of pDNA or siRNA.  Despite the 
~100-fold difference in molecular weight between a single siRNA duplex and pDNA 
molecule, polyplexes prepared with both nucleic acid types have comparable size and 
display similar dependences of size on concentration.  PEGylation of both siRNA-
containing and pDNA-containing polyplexes (via AD-PEG) confers salt stability, sharply 
reduces variation in size with formulation concentration, and lowers measured surface 
charge (zeta potential).  Flow cytometry and fluorescence microscopy are used to 
demonstrate that siRNA-containing polyplexes are readily endocytosed by cultured cells, 
and an in vitro serum stability assay indicates that siRNA within these polyplexes is 
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protected from serum nuclease degradation.  A method is developed to quantify the amount 
of polymer bound (vs. unbound) within siRNA- and pDNA-containing polyplexes; for both 
nucleic acid types and at all overall charge ratios examined, this amount is just enough to 
provide sufficient positive charges to balance the negative charges within the nucleic acids.  
Taken together, these results suggest that CDP/siRNA polyplexes will be suitable for RNAi 
applications in cultured cells and in vivo. 
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3.3 METHODS 
3.3.1 Polymers 
Unless otherwise noted, an imidazole-terminated, cyclodextrin-containing polycation 
(CDP) was used for all studies and synthesized as described previously1,13.  Adamantane-
poly(ethylene glycol) (AD-PEG) conjugates, made with PEG5000, were synthesized as 
described previously8.  Ligand-containing modifiers, including lactose (AD-PEG-Lac) and 
transferrin (AD-PEG-Tf), were synthesized as described previously13,15. 
3.3.2 Nucleic acids 
For all DNA-containing samples, the pGL3-Control Vector (Promega) was used.  For all 
samples containing unlabeled siRNA, the “Luciferase GL3 duplex” (“siGL3,” 
Dharmacon), was used.  Fluorescein-labeled siRNA (single, covalent fluorescein 
modification at the 5’ end of the sense strand; “FL-siRNA”) used was the “FL-siGL2” 
duplex (Dharmacon).  Sequences: 
 
siGL3: 
5’-CUUACGCUGAGUACUUCGAdTdT-3’ 
3’-dTdTGAAUGCGACUCAUGAAGCU-5’ 
 
FL-siGL2: 
5’-[Fluorescein]CGUACGCGGAAUACUUCGAdTdT-3’ 
          3’-dTdTGCAUGCGCCUUAUGAAGCU-5’ 
 
3.3.3 Gel retardation studies 
Solutions of either pDNA or siRNA were prepared by diluting 0.5 µg nucleic acid to a 
concentration of 0.1 µg/µL in distilled water.  An equal volume (5 µL) of CDP (at various 
concentrations) was added to each pDNA or siRNA solution; the resulting 10-µL solutions 
were incubated at room temperature for 30 min to allow polyplex formation.  Two 
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microliters of loading buffer (0.03% bromophenol blue, 0.03% xylene cyanol FF, 10 mM 
Tris-HCl, 50 mM EDTA) were added to each polyplex solution, and 10 µL (of a total of 12 
µL) of the resulting solutions were loaded per well of a 1% (for pDNA-containing samples) 
or 4% (for siRNA-containing samples) agarose gel in 1x TAE buffer (40 mM Tris-Acetate, 
1 mM EDTA, pH 8.3) with 0.1 µg/mL ethidium bromide.   Gels were electrophoresed at 
100 V for 60 min before visualization. 
Charge ratio calculations were made based on each CDP repeat unit having two positive 
charges and a molecular weight of 1460 Da and each pDNA/siRNA repeat unit (base pair) 
having two negative charges and a molecular weight of 660 Da.  The desired charge ratios 
(0, 0.5, 1, …, 5 +/-) correspond to the following concentrations: 
Charge 
Ratio (+/-) 
CDP-Im 
(5 µL) 
siGL3 or pDNA 
(5 µL) 
0 0 mg/mL 0.1 mg/mL 
0.5 0.1106 mg/mL 0.1 mg/mL 
1 0.2212 mg/mL 0.1 mg/mL 
1.5 0.3318 mg/mL 0.1 mg/mL 
2 0.4424 mg/mL 0.1 mg/mL 
2.5 0.553 mg/mL 0.1 mg/mL 
3 0.6636 mg/mL 0.1 mg/mL 
3.5 0.7742 mg/mL 0.1 mg/mL 
4 0.8848 mg/mL 0.1 mg/mL 
4.5 0.9954 mg/mL 0.1 mg/mL 
5 1.106 mg/mL 0.1 mg/mL 
 
3.3.4 Dynamic light scattering (DLS) studies of polyplex size and zeta potential. 
A CDP solution (in distilled water) was added to an equal volume containing 2 µg of 
pDNA or siRNA at a charge ratio of 3/1 +/-.  While the charge ratio was fixed, four 
different concentration combinations of CDP and nucleic acid were examined: 
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Sol’n CDP pGL3CV or siGL3 H2O 
A 20 µL @ 0.6636 mg/mL 20 µL @ 0.1 mg/mL 1160 µL 
B 50 µL @ 0.2654 mg/mL 50 µL @ 0.04 mg/mL 1100 µL 
C 100 µL @ 0.1327 mg/mL 100 µL @ 0.02 mg/mL 1000 µL 
D 600 µL @ 0.02212 mg/mL 600 µL @ 0.00333 mg/mL (0 µL) 
 
The resulting solutions were incubated at room temperature for 30 min to allow polyplex 
formation.  An appropriate volume of distilled water (indicated in the above table) was then 
added to give a total sample volume of 1200 µL. 
For formulations PEGylated after polyplex formation (“post-PEGylated”), an appropriate 
amount of an AD-PEG solution (4.95 µL of a 20 mg/mL AD-PEG solution, corresponding 
to a 1:1 molar ratio of AD:β-CD) was added prior to “voluming up” to a total sample 
volume of 1200 µL with water. 
For formulations PEGylated before polyplex formation (“pre-PEGylated”), an appropriate 
amount of an AD-PEG solution (4.95 µL of a 20 mg/mL AD-PEG solution, corresponding 
to a 1:1 molar ratio of AD:β-CD) was added to CDP.  The resulting CDP/AD-PEG solution 
was added to the nucleic acid solution and subsequently “volumed up” to a total sample 
volume of 1200 µL with water. 
Polyplex solutions were loaded into polystyrene cuvettes and polyplex size (effective 
hydrodynamic diameter) was determined by dynamic light scattering (DLS) using a 
ZetaPALS (Brookhaven Instruments) instrument.  Ten successive measurements of 30 sec 
each were performed.  For appropriate samples, 600 µL phosphate-buffer saline (PBS) 
solution was added after the fifth measurement.  After measuring polyplex size, the surface 
charge (zeta potential) of polyplex solutions was subsequently measured using the same 
instrument (Smoluchowski method, 10 runs, target residual = 0.05, pH = 6.0, SR-101 
(solvent-resistant) device). 
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3.3.5 Flow cytometry and confocal microscopy to assess polyplex uptake 
HeLa (human cervical carcinoma) cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (CellGro) supplemented with 10% fetal bovine serum (Invitrogen) and 1x 
antibiotic-antimycotic solution (Invitrogen).  5 x 104 cells were plated in 1 mL growth 
medium per well of a 24-well tissue culture plate 24 h prior to transfection.  UnPEGylated 
CDP/FL-siRNA polyplexes containing 1 µg siRNA at a charge ratio of 3/1 (+/-) were 
prepared as described above.  For flow cytometry, cells were detached with trypsin and 
rinsed twice with PBS (containing 0.1% BSA), prior to analysis using a FACScalibur 
(Becton Dickinson).  For laser scanning confocal microsopy, cells were rinsed with PBS 
and fixed with 4% formaldehyde in 100 mM HEPES for 15 min.  Following two more PBS 
washes, cells were left in PBS, and microscopy was conducted using a Zeiss 410 laser 
scanning confocal microscope. 
3.3.6 Serum nuclease stability 
For each sample, 5 µL of active mouse serum (Sigma) was added to an equal volume of 
water containing 40 pmol siGL3, either naked or within CDP-containig polyplexes (3/1 
(+/-) charge ratio); serum was added either before or after a 4 h incubation at 37 oC, as 
indicated.   Following this incubation, 2 µL of loading buffer (0.03% bromophenol blue, 
0.03% xylene cyanol FF, 10 mM Tris-HCl, 50 mM EDTA) were added to each solution, 
and 10 µL (of a total of 12 µL) of the resulting solutions were loaded per well of a 15% 
polyacrylamide gel in 1x TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA).   The 
gel was electrophoresed at 100 V for 75 min, then incubated in 50 mL 1x TBE buffer 
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containing 0.1 µg/mL ethidium bromide with gentle shaking for 30 min to allow 
visualization. 
3.3.7. Measurement of unbound polymer 
pDNA-containing or siRNA-containing polyplexes were prepared using 1 µg nucleic acid 
and an amine-terminated CDP at various charge ratios.  To each 100-µL polyplex solution, 
575 µL water and 75 µL 10x PBS was added, giving a final 750-µL solution of polyplexes 
in 1X PBS.  These solutions were centrifuged at 20,800*g for 99 min to pellet aggregated 
polyplexes.  500 µL of each supernatant was then used for determination of unbound CDP 
via end-group analysis (amine quantification) using a TNBS assay as described 
previously21.  Using a CDP standard curve, the amount of free CDP for the entire sample 
was calculated and subtracted from the total CDP to determine the amount of CDP bound.  
This mass of CDP was converted to an equivalent charge ratio, an “effective polyplex 
charge ratio” (EPCR), as described above. 
3.3.8 Isothermal titration calorimetry (ITC) 
All calorimetric measurements were performed using a MCS ITC calorimeter (Microcal) 
running MCS Observer and Origin software.  The titrant syringe (250-µL volume) was 
loaded with a 12.68 mg/mL solution of AD-PEG in water (corresponding to [AD] = 2.226 
mM).  The sample cell (1.5-mL volume) was loaded with a solution of β-CD alone, CDP 
alone, or CDP/pDNA polyplexes of various charge ratios; for all of these solutions, the 
concentration of β-CD moieties was kept constant ([β-CD] = 0.225 mM).  After a 2-µL 
pre-injection (as recommended by the manufacturer), twenty-five successive AD-PEG 
injections of 10 µL each were made.  The heat added or removed in order to keep the cell at 
constant temperature (20 oC) was measured as a function of time.  Using Origin software 
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provided by the manufacturer, this data was regressed to give best-fit values for 
stoichiometry (n; number of ligand binding sites), binding strength (K; M-1), and enthalpy 
of binding (∆H; kcal/mol of injectant). 
3.3.9 Turbidity analysis 
Polyplexes were made with 1 µg pDNA and amine-terminated CDP at a charge ratio of 3/1 
(+/-) as described above.  To each 200-µL polyplex solution, 20 µL of water or an AD-
PEG solution (to give 1:1 AD:β-CD (“100%”) or 3:1 AD:β-CD (“300%”) was added.  
Then 1000 µL PBS was added, and resulting solutions were incubated at 37 oC for 1 h.  
Solution absorbance at 405 nm (A405) was then measured. 
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3.4 RESULTS 
3.4.1 CDP condenses siRNA into polyplexes 
Given the electrostatic basis of interaction between our cyclodextrin-containing polycation 
(CDP), we hypothesized that the amounts of CDP required to bind siRNA would be similar 
to that observed previously with pDNA1.  For each of these two nucleic acid types, samples 
were prepared in which increasing concentrations of CDP were added to a given 
concentration of nucleic acid.  The resulting solutions were electrophoresed on a 
polyacrylamide (for siRNA-containing samples) or an agarose (for pDNA-containing 
samples) gel (Fig. 3.4). 
 
Figure 3.4. Gel retardation assay for CDP/siRNA and CDP/pDNA polyplexes. 
Increasing amounts of CDP were added to 0.5 µg of (a) pDNA or (b) siRNA, and resulting 
solutions were analyzed by gel electrophoresis.  For both nucleic acids, complete 
retardation was observed for all charge ratios greater than 1 +/-. 
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Unbound nucleic acids can migrate freely through the gel, whereas CDP-bound nucleic 
acids are trapped within the wells into which they are loaded.  For both pDNA and siRNA, 
as soon as the amount of CDP added created a positive (i.e., greater than 1/1 +/-) charge 
ratio, all nucleic acids remained within the wells.  This observation suggests that, analogous 
to what has been seen here and previously with pDNA, formulation of siRNA with CDP at 
a positive charge ratio is sufficient to condense all siRNA within polyplexes. 
Because the molecular weight of the siRNA examined here (~1 x 104 Da) is only a fraction 
of that of the pDNA (~1 x 106 Da), we wondered how the sizes of CDP/siRNA and 
CDP/pDNA polyplexes would compare.  The sizes (hydrodynamic diameters) of a number 
of polyplex samples were determined by dynamic light scattering (DLS); the results are 
shown in Figure 3.5. 
 
Figure 3.5. Determination of CDP/siRNA and CDP/pDNA polyplex size by dynamic 
light scattering. CDP/siRNA and CDP/pDNA polyplexes were prepared at the same 
charge ratio (3 +/-) but at a variety of concentrations.  siRNA- and pDNA-containing 
polyplexes exhibit a very similar dependence of size on formulation concentration: the 
more dilute the components are at formulation, the smaller the resulting polyplexes are. 
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The size of pDNA-containing polyplexes, all of which were prepared at the same charge 
ratio (3 +/-), shows a strong dependence on concentration.  The more concentrated the 
components are at the time of formulation, the larger the diameters of the resulting 
polyplexes.  These results suggest that, as formulation concentrations increase, the number 
densities and/or mass densities of the polyplexes decrease. 
3.4.2 PEGylation of CDP/siRNA polyplexes confers salt stability and reduces 
dependence of size on concentration 
 
Previous work with CDP/pDNA polyplexes has shown that addition of an adamantane-
poly(ethylene glycol) (AD-PEG) conjugate confers stability when polyplexes are exposed 
to salt8.  After adding CDP to siRNA to form polyplexes, DLS was used to monitor 
polyplex size both in water and after addition of salt (phosphate-buffered saline, PBS); 
these results are compared to those for CDP/pDNA polyplexes and to those to which AD-
PEG was added (Fig. 3.6). 
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Figure 3.6. AD-PEG confers salt stability to CDP/siRNA polyplexes. The sizes of 
CDP/siRNA and CDP/pDNA polyplexes (3 +/-) were analyzed by DLS for ten consecutive 
runs; PBS was added after the fifth run.  Polyplex effective diameters are presented as a 
percentage of the initial size (first run) for each sample.  For both types of nucleic acids, the 
addition of AD-PEG sharply reduces salt-induced polyplex aggregation. 
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As is seen for polyplexes containing pDNA, AD-PEG confers salt stability to CDP/siRNA 
polyplexes. 
We have previously observed for DNA-containing polyplexes that addition of AD-PEG to 
CDP prior to polyplex formation (“pre-PEGylation”) eliminates the concentration 
dependence on size that is seen for unPEGylated polyplexes (see Fig. 3.5) and for those to 
which AD-PEG is added after polyplex formation (data not shown).  The sizes of pre-
PEGylated CDP/siRNA and CDP/pDNA polyplexes were measured at numerous 
formulation concentrations (Fig. 3.7). 
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Figure 3.7. Pre-PEGylation generates CDP/siRNA polyplexes of uniform, small size 
and reduces their zeta potential. (a) The sizes of pre-PEGylated CDP/siRNA and 
CDP/pDNA polyplexes (3 +/-) prepared at various concentrations were analyzed by DLS.  
Results for unPEGylated polyplexes made under the same conditions (see Fig 3.5) are 
included here for comparison.  For both types of nucleic acids, the addition of AD-PEG to 
CDP prior to polyplex formation (“pre-PEGylation”) sharply reduces variation in polyplex 
size with formulation concentration. (b) The zeta potentials of all sixteen samples (four 
formulations at four different concentrations each) were measured; bars represent averages 
and error bars represent standard deviation.  PEGylation of CDP/pDNA and CDP/siRNA 
polyplexes significantly reduces their zeta potential. 
 
3.4.3 CDP/siRNA polyplexes are readily endocytosed by cultured cells 
Our previous work with CDP/pDNA polyplexes has shown high levels of cellular uptake 
when they are exposed to adherent cells in culture7.  Here, polyplexes were prepared with 
CDP and siRNA duplexes that were covalently modified to contain fluorescein at their 5’ 
ends (FL-siRNA).  Uptake of these polyplexes was assessed through examination of 
cellular fluorescence by flow cytometry and confocal microscopy (Fig. 3.8). 
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Figure 3.8. CDP/siRNA polyplexes are readily taken up by adherent cultured cells. 
HeLa cells were exposed to CDP/FL-siRNA polyplexes for 2 h prior to assessment of 
cellular fluorescence by (a) flow cytometry and (b) confocal microscopy.  Virtually all 
(>99%) cells exhibit strong fluorescence suggestive of polyplex uptake; neither FL-siRNA 
alone nor polyplexes containing unlabeled siRNA generated any significant cellular 
fluorescence. 
 
Negative control samples, uncomplexed FL-siRNA and polyplexes containing unlabeled 
siRNA, induced negligible (<1%) increases in cellular fluorescence relative to the untreated 
cells.  However, CDP/FL-siRNA polyplexes caused significant fluorescent signal in 
virtually all (>99%) cells that were exposed.  By comparison, a commonly used and 
commercially available lipid reagent for the delivery of siRNA (Oligofectamine) generated 
just 43% positive cells under the same conditions.  The strong cellular fluorescence 
measured for the CDP/FL-siRNA sample was confirmed by confocal microscopic analysis.  
These results indicate there is substantial uptake of CDP/siRNA polyplexes by cultured 
HeLa cells, strengthening the hypothesis that achieving down-regulation of a target gene in 
these cells is a possibility. 
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3.4.4 siRNA within polyplexes is protected from serum nuclease degradation 
While CDP/siRNA polyplexes are taken up to a great extent by cultured cells (see Section 
3.4.3), polyplexes that are administered in vivo will encounter additional barriers to 
targeted gene down-regulation.  The first of these obstacles encountered after injection will 
be the nuclease-rich environment of the blood.  It has been shown by several researchers 
that, under “normal” delivery conditions (i.e., low-pressure injections) unmodified siRNA 
duplexes will not be efficiently endocytosed by cells and therefore will not achieve desired 
gene down-regulation in vivo16-18.  This is due to the rapid degradation of the siRNA 
duplexes by nuclease proteins within the blood.  To avoid this degradation, researchers 
have employed numerous chemical modifications to the siRNA, most notably changing the 
interbase linkages from phosphodiesters to phosphorothioates19-20.  We expect that siRNA 
within our polyplexes may be protected from nuclease degradation, thereby eliminating the 
need to use more costly, chemically-modified duplexes. 
In order to examine what protection, if any, CDP affords siRNA within polyplexes, siRNA 
alone and within CDP/siRNA polyplexes were exposed to active mouse serum and then 
analyzed by gel electrophoresis (Figure 3.9). 
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Figure 3.9. CDP protects siRNA duplexes from serum nuclease degradation. 
CDP/siRNA polyplexes were exposed to active mouse serum at 37 oC for 4 h prior to 
polyacrylamide gel electrophoresis.  Uncomplexed siRNA, either in water (no serum; lane 
1) or with only a momentary exposure to serum (lane 2) are included as negative controls 
for degradation.  Heparan sulfate, which displaces CDP/siRNA polyplexes21, was added 
immediately prior to gel loading in lane 5.  After a 4 h exposure to active mouse serum, 
siRNA that is displaced from CDP/siRNA polyplexes appears to be intact. 
 
When incubated in water (no serum) prior to gel electrophoresis, the siRNA gives a strong, 
single band (see lane 1).  Addition of mouse serum immediately prior to gel loading (a “t=0 
 exposure; see lane 2) has no significant effect on the siRNA migration or intensity, 
suggesting that more time is needed to induce degradation.  A 4 h exposure to serum, 
however, leads to complete degradation of uncomplexed siRNA (see lane 3).  When 
CDP/siRNA polyplexes are subjected to the same conditions and then directly 
electrophoresed, all of the siRNA remains CDP-bound within the well of the gel (see lane 
4).  This observation is expected based on previous gel retardation analysis (see Fig. 3.4) 
for the 3 +/- charge ratio employed here.  When heparan sulfate is added to serum-treated 
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polyplexes to displace the siRNA from CDP, the single siRNA band returns.  This suggests 
that siRNA duplexes within CDP/siRNA polyplexes are protected from nuclease 
degradation when exposed to active mouse serum. 
3.4.5 Measurement of unbound CDP and “effective polyplex charge ratio” 
The results shown previously in this chapter demonstrate that CDP can condense siRNA 
duplexes into polyplexes that are suitable for cellular uptake and protect the siRNA from 
degradation.  It is clear that complete condensation of siRNA can be achieved for all 
positive charge ratios (greater than 1/1 +/-; see Figure 3.4).  But it is unclear from a simple 
gel retardation study whether all of the “excess” CDP participates in siRNA binding or if 
some of it remains uncomplexed, as “bystander” CDP molecules.  To investigate this 
unbound polymer, an assay was developed to quantify the amount of uncomplexed CDP 
within unPEGylated polyplex formulations. 
Figure 3.6 demonstrates that unPEGyated polyplexes (containing either pDNA or siRNA) 
rapidly aggregate when exposed to salt.  Solutions of aggregated polyplexes are then 
centrifuged at high speed to pellet aggregates, leaving any unbound components within 
supernatants.  Indeed, UV/Vis spectrophotometric analysis has confirmed the absence of 
nucleic acid within these supernatants (data not shown), suggesting that all polyplexes are 
within aggregates that have been pelleted by centrifugation.  Unbound CDP in supernatants 
is then quantified by end-group analysis21 and subtracted from the total amount of CDP 
within the formulation (bound plus unbound) to calculate the amount of CDP within the 
(aggregated) polyplexes—this amount of bound CDP is used to calculate an “effective 
polyplex charge ratio” (EPCR) that is reflective of the actual composition of the polyplexes 
within a given formulation. 
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EPCR results for CDP/pDNA and CDP/siRNA polyplexes are shown in Figure 3.10. 
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Figure 3.10. The amount of bound CDP within formulations is independent of overall 
formulation charge ratio. CDP/pDNA and CDP/siRNA polyplexes were formulated at a 
variety of overall charge ratios (from 2 to 30 +/-).  PBS was added to induce polyplex 
aggregation, and aggregated polyplexes were pelleted by centrifugation.  The amount of 
unbound CDP in the resulting supernatants was quantified by TNBS assay and subtracted 
from the total amount of CDP within the formulation to determine the amount of bound 
CDP within polyplexes; this amount of bound CDP was used to calculate the “effective 
polyplex charge ratio” (EPCR) on the polyplexes.  All data points fall along the y = 1 line, 
corresponding to an EPCR of about 1/1 (+/-). 
 
For all of the charge ratios examined, the amount of unbound CDP recovered in the 
supernatants scaled with the total amount of CDP within the formulation.  As a 
consequence, the amount of bound CDP across these formulations was about the same; this 
amount corresponded to an effective charge ratio on the polyplex of about 1/1 +/-.   From 
these observations, it appears that the amount of CDP within polyplexes is just enough to 
provide an equivalent amount of positive charges to balance the negative charges 
contributed by the phosphodiester backbones of the nucleic acids.  Further, it can be 
concluded that any differences seen in formulations at high charge ratios (such as toxicity 
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seen in some cell lines at very high charge ratios1 may be attributed to the unbound CDP 
within these formulations. 
3.4.6 Stoichiometry and strength of AD-PEG/CDP binding: isothermal titration 
calorimetry (ITC) 
 
Because of their aggregation in salt, unmodified CDP/siRNA polyplexes are unsuitable for 
in vivo administration.  Addition of an adamantine-poly(ethylene glycol) (AD-PEG) 
conjugate to these polyplexes stabilizes them to salt (see Figure 3.6); the adamantane 
moiety of AD-PEG forms an inclusion complex with the β-CD moieties within CDP.  
While the effect of AD-PEG addition was clear, little was known about the stoichiometry 
and binding strength of this PEGylation.  These parameters were examined by isothermal 
titration calorimetry (ITC). 
Sequential additions of an AD-PEG solution were made to an isothermal cell containing 
either a β-CD solution, a CDP solution, or CDP/pDNA solutions of varying charge ratio 
(all having same concentration of β-CD moieties).  Non-linear least squares analysis of the 
resulting heat curves determined a stoichiometry of binding (moles AD per mole β-CD) 
and enthalpy of binding (∆H) (Fig. 3.11). 
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Figure 3.11. Isothermal titration calorimetry (ITC) analysis of AD-PEG binding to β-
CD, CDP, and CDP-containing polyplexes. A syringe is loaded with an AD-PEG 
solution, from which aliquots are injected into an isothermal cell containing a solution of β-
CD, CDP alone, or CDP/pDNA polyplexes.  The heat required to maintain the cell at 
constant temperature is measured, and a non-linear least squares regression is performed to 
determine stoichiometry and strength of binding. (a) Representative plot of an AD-PEG/β-
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CD ITC run. (b) Fitted n values (moles AD bound per mole β-CD). (c) Fitted ∆H values (-
1 * (calories per mol AD injected)).  Stoichiometry results suggest that the majority of β-
CD moieties within bound CDP molecules are unoccupied by AD-PEG.  The increased 
binding energy on polyplexes suggests additional cooperative interactions among AD-PEG 
molecules on the polyplex surface. 
 
ITC analysis of AD-PEG/β-CD interactions generated an equilibrium stoichiometry of n = 
0.991, in excellent agreement with the expected value of 1 (AD and β-CD are known to 
exhibit 1:1 mol:mol binding12).  The observed binding constant, K = 3.75 x 104 M-1 (data 
not shown), is in excellent agreement with literature values for AD/β-CD inclusion 
complexes12. When AD-PEG was added to a solution of CDP (containing the same 
concentration of β-CD moieties), the observed stoichiometry dropped to n = 0.55.  This 
result suggests that, for a pre-PEGylated formulation prepared with equimolar AD-PEG 
and CDP (with respect to AD and b-CD moieties), just over half of the β-CD cavities are 
occupied.  CDP/pDNA polyplexes at a 30/1 (+/-) charge ratio give a stoichiometry almost 
identical to that of free CDP (n = 0.57).  Given the previous finding that the effective 
polyplex charge ratio is 1/1 (+/-), one would expect 29/30 (96.7%) of CDP molecules 
within a 30/1 (+/-) formulation to be unbound, and, therefore, the ITC results to be almost 
identical to those of CDP alone.  As the polyplex charge ratio is reduced from 30/1 (+/-) to 
3/1 (+/-), the fraction of unbound CDP molecules drops, and the stoichiometry determined 
by ITC decreases from n = 0.57 to n = 0.17.  This observation strongly suggests that, when 
AD-PEG is added to polyplexes after they have already been formed (“post-PEGylated”), 
the overwhelming majority (83%) of β-CD moieties remain unoccupied.  The binding 
energy seen for polyplexes formed at 3/1 (+/-), -23 kcal/mol, is significantly higher than 
that seen for 30/1 (+/-) polyplexes or CDP alone (-6.9 kcal/mol and –6.7 kcal/mol, 
respectively).  This result implies that there are cooperative interactions occurring between 
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AD-PEG molecules on the polyplex surface, perhaps through formation of a PEG “brush” 
layer22.  
These ITC results also imply that, due to the low occupancy of β-CD moieties within CDP-
containing polyplexes, adding an excess amount of AD-PEG (moles AD > moles β-CD) 
may confer additional stability.  This was confirmed through a turbidity assay developed as 
an alternative method (to DLS) to assess polyplex aggregation.  Polyplexes were pre-
PEGylated or post-PEGylated with AD-PEG at either a 1:1 (AD:β-CD mol:mol, “100%”) 
or 3:1 (“300%”) ratio prior to incubation with PBS; aggregation (turbidity) was assessed by 
measurement of solution absorbance at 405 nm (Fig. 3.12). 
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Figure 3.12. Addition of “excess” AD-PEG leads to enhanced protection of 
CDP/pDNA polyplexes from salt-induced aggregation.  Water and PEGylated or 
unPEGylated CDP/pDNA polyplexes were incubated with phosphate-buffered saline 
(PBS) for 1 h at 37 oC followed by measurement of solution absorbance at 405 nm (A405).  
While equimolar addition of AD-PEG (“100%”), either before or after polyplex formation, 
sharply reduces the increase in A405 seen for unPEGylated polyplexes, addition of even 
more AD-PEG (“300%”) completely abrogates any increase in A405 value.  
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Equimolar AD-PEG addition reduced turbidity by >90%, but a three-fold excess of AD-
PEG completely abrogated PBS-induced turbidity.  This result provides functional 
confirmation for the hypothesis from previous ITC analysis (see Fig. 3.11) that polyplexes 
PEGylated with equimolar AD-PEG retain the capacity for additional PEGylation. 
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3.5 DISCUSSION 
The experimental results presented in this chapter suggest that the natures of CDP-
containing polyplexes made with either pDNA or siRNA are very similar.  An equal mass 
of either nucleic acid appears to require the same amount of CDP for condensation, and the 
resulting polyplexes have similar sizes and exhibit the same concentration-dependence.  
Modification of both types of polyplexes with AD-PEG reduces salt-induced aggregation 
and lowers surface charge (zeta potential). 
Because the fundamental nature of pDNA and siRNA is much the same (linear 
arrangements of nucleotides connected by phosphodiester linkages), it is not surprising that 
polyplexes can be formed with either by addition of CDP under the same conditions.  
However, the difference in size between a single pDNA molecule (the plasmid here had 
5256 bp, corresponding to a molecular weight of ~3.5 x 106 Da) and an siRNA molecule 
(the siRNA duplex used here has a molecular weight of 1.33 x 104 Da) is about two orders 
of magnitude.  It stands to reason from the experimental results shown above that the 
amount of CDP within polyplexes, on a per-polyplex basis, is similar for pDNA- and 
siRNA-containing complexes.  It follows, then, that the number of siRNA molecules per 
polyplex (the “siRNA payload”) is much greater than is observed for pDNA.  (As is 
discussed in Chapter 5, multi-angle light scattering (MALS) analyses of CDP/pDNA 
polyplexes suggest that the number of pDNA molecules per polyplex is very small (~1-
2)23.) 
As was mentioned above (see Section 3.2), microscopic analyses of cultured cells exposed 
to polyplexes made with fluorescently-labeled DNA indicate that the majority of 
intracellular complexes are sequestered within endocytic vesicles.  Even with an imidazole-
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terminated CDP that enhances polyplex-mediated gene expression and appears to aid in 
vesicular release and/or polyplex unpackaging, detection of nucleic acid outside of these 
vesicles, either CDP-bound or free, is extremely difficult7.  This implies that an escape of 
polyplexes from endocytic vesicles is a rare event.  Therefore, given the rarity of polyplex 
escape from intracellular vesicles, the presumably heightened payload per polyplex when 
siRNA is used (compared to pDNA), and the fact that RNAi occurs in the cytoplasm (while 
transcription of delivered genes takes place in the nucleus), it seems entirely possible that 
siRNA-containing polyplexes will be more potent RNAi effectors than pDNA-containing 
polyplexes are gene delivery agents.  The investigation of CDP/siRNA polyplexes to 
accomplish RNAi is the subject of the next chapter. 
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CHAPTER 4: In Vitro and In Vivo Efficacy of CDP/siRNA Polyplexes 
 
 
4.1 ABSTRACT 
Synthetic siRNA duplexes have been shown to be non-immunogenic in cultured cells and 
in mice and, when administered by high-pressure (“hydrodynamic”) tail vein injection, can 
be effective agents of targeted gene down-regulation in mouse liver.  The method of 
delivery is infeasible for human therapeutic applications, however, prompting the 
investigation of non-viral systems, including our cyclodextrin-containing polycation (CDP) 
system, as appropriate delivery agents.  This CDP system has been demonstrated to 
condense siRNA duplexes into small (<100 nm), well-defined complexes that are suitable 
for cellular uptake and protect the siRNA from nuclease degradation.  Here, the efficacy of 
CDP/siRNA complexes to down-regulate both endogenous and exogenous target genes is 
examined in vitro and in vivo.  These complexes are capable of eliciting an RNA 
interference (RNAi) effect in cultured cells, as shown through examples with an exogenous 
reporter gene (luciferase) and an endogenous oncogene (EWS-Fli1).  When these 
polyplexes are modified to contain an appropriate targeting ligand, down-regulation of a 
transgene in mouse liver (via a galactose ligand) and therapeutic inhibition of tumor 
formation in mice (using a transferrin ligand) can be achieved.   These results demonstrate 
the tremendous promise of a CDP-based system for targeted delivery of siRNA for 
therapeutic in vivo applications. 
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4.2 INTRODUCTION 
A tremendous amount of research is being performed to better understand the mechanism 
of RNA interference (RNAi) in mammalian cells, making in vivo therapeutic applications 
of RNAi increasingly likely to emerge soon. However, systemic applications of virally 
delivered small interfering RNA (siRNA) duplexes and related RNAi products are unlikely 
to be viable in the near future, due to host immune responses upon repeated delivery and 
ineffective tumor targeting. The systemic, non-viral delivery of RNAi molecules has been 
reported in mice and initially involved high-pressure, high-volume tail-vein injections of 
naked nucleic acids1-3; this method is untenable and unacceptable in humans in routine 
clinical settings. Subsequently, naked siRNA4-6, lipid-formulated siRNA7, plasmids 
expressing short hairpin RNA8-9, and polycation-formulated siRNA10-12 have been 
administered systemically in mice. Naked or formulated siRNAs have also been directly 
injected into xenograft tumors in mice13-16.  Naked siRNAs require chemical stabilization 
for in vivo use6,17, have non-specific biodistributions that are the same as single-stranded 
antisense agents18, and require large and repeated dosages for efficacy6.  Further, while 
synthetic siRNAs themselves have been shown to be non-immunogenic in mice19, some in 
vivo administrations of lipid formulations have been associated with immunogenicity20-22.  
Thus the need for the development of a safe, effective non-viral delivery system for siRNA 
remains. 
The synthesis and characterization of cyclodextrin-containing polycations that can bind and 
condense DNA into polymer-DNA complexes (“polyplexes”) suitable for cellular uptake 
have been described23-24.  These can be stabilized by incorporation of a neutral polymer 
(poly(ethylene glycol); PEG) tethered to a hydrophobic small molecule (adamantane; AD) 
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that interacts strongly with the interior of β-cyclodextrin moieties within the polymer via 
inclusion complex formation25.  Further, these AD-PEG conjugates can be modified by 
addition of a targeting ligand, such as transferrin (Tf), to endow polyplexes with selectivity 
for cells that express high levels of a cognate cell surface receptor26-27.   As was discussed 
in Chapter 3, this delivery system is suitable for formulation with siRNA duplexes as well.  
CDP/siRNA polyplexes can be readily taken up by cells, and the siRNA within them is 
protected from serum nuclease degradation. 
In this chapter, the ability of siRNA-containing polyplexes to achieve target gene down-
regulation is examined, both in cultured cells and in mice.  Sequence-specific knockdown 
of a co-delivered reporter gene (luciferase) by CDP/siRNA polyplexes is shown in two 
different cell lines.  Evidence of down-regulation of a chimeric oncogene (EWS-Fli1) in 
cultured Ewing’s sarcoma cells is also provided.  The efficacy of targeted polyplexes in 
two different in vivo systems is also shown.  Galactose-bearing polyplexes elicit down-
regulation of luciferase within the livers of transgenic mice.  Transferrin-targeted 
complexes reduce EWS-Fli1 levels in Ewing’s tumors, and long-term delivery of these 
complexes inhibits tumor growth.  Finally, and perhaps most importantly, the safety (as 
measured by histology, critical blood counts (CBC), and liver function) and non-
immunogenicity of these polyplexes, even when containing an siRNA duplex possessing a 
putative immunostimulatory motif, are demonstrated.  
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4.3 METHODS 
 
4.3.1 Polymers 
Unless otherwise noted, an imidazole-terminated, cyclodextrin-containing polycation 
(CDP) was used for all studies and synthesized as described previously23,26.  An 
adamantane-poly(ethylene glycol) (AD-PEG) conjugate, made with PEG5000, was 
synthesized as described previously26.  A transferrin-containing modifier, (AD-PEG-Tf), 
was synthesized as described previously26.  Another ligand-containing modifier, 
adamantane-poly(ethylene glycol)-lactose (AD-PEG-Lac), was prepared as described 
(using PEG5000 instead of PEG3400)28. 
4.3.2 Nucleic acids 
A plasmid encoding the firefly luciferase gene (“pGL3-Control Vector,” pGL3CV) was 
purchased from Promega.  siRNA duplexes were used that target luciferase (“Luciferase 
GL3 duplex,” siGL3); enhanced green fluorescent protein (siEGFP); the EWS-Fli1 fusion 
gene (siEFBP2)29, a mutated, non-targeting version of siEFBP2 (siEFBP2mut); and a non-
targeting control sequence (“siCONTROL Non-Targeting Duplex #1,” siCON1).  All were 
chemically synthesized by Dharmacon and used as received.  Sequences: 
siGL3: 
   5’-CUUACGCUGAGUACUUCGAdTdT-3’ 
3’-dTdTGAAUGCGACUCAUGAAGCU-5’ 
 
siEGFP: 
5’-CUUACGCUGAGUACUUCGAdTdT-3’ 
3’-dTdTGAAUGCGACUCAUGAAGCU-5’ 
 
siEFBP2: 
     5’-GCAGAACCCUUCUUAUGACUU 
  UUCGUCUUGGGAAGAAUACUG-5’ 
 
siEFBP2mut: 
     5’-GCAGAACCAGUCUUAUGACUU 
  UUCGUCUUGGUCAGAAUACUG-5’ 
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siCON1: 
     5’-UAGCGACUAAACACAUCAAUU 
  UUAUCGCUGAUUUGUGUAGUU-5’ 
 
[The mutated nucleotides within siEFBP2mut are indicated in bold; the putative 
immunostimulatory motif within siCON1 is underlined.] 
4.3.3 HeLa and BHK transfections, luciferase assays 
HeLa and BHK cells (American Type Culture Collection) were cultured in Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% fetal bovine serum and 1x antibiotic-
antimycotic (penicillin, streptomycin, and amphoterecin B).  Cells were seeded in 24-well 
plates at 50,000 cells per well 24 h prior to transfection.  Polyplexes were prepared with 
pGL3CV alone or in combination with siGL3 or siEGFP at a charge ratio of 3/1 (+/-).  
Lipoplexes were prepared with the same nucleic acid combinations using Lipofectin 
(Invitrogen) according to the manufacturer’s instructions.  For all polyplex and lipoplex 
samples, each well received 1 µg pDNA and 100 nM of the indicated siRNA.  Complexes 
were incubated with cells in serum-free medium (OptiMEM, Invitrogen) for 4 h, after 
which solutions were aspirated and replaced with complete growth medium.  At a total of 
48 h post-transfection, growth medium was aspirated and replaced with 100 µL 1x Cell 
Culture Lysis Reagent (Promega).  Plates were incubated at room temperature with gentle 
shaking for ~1 h to allow complete cell lysis.  The luminescence of cell lysates was then 
determined using a Monolight 3010 luminometer (BD Pharmingen) and the Luciferase 
Assay System (Promega).  One hundred microliters substrate solution was added to 10 µL 
cell lysate, and the resulting luminescent signal was integrated over 10 sec. 
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4.3.4 TC71 transfection, Western blot 
TC71 cells (provided by Dr. Timothy Triche, Children’s Hospital—Los Angeles) were 
cultured in RPMI 1640 medium with 10% fetal bovine serum (no antibiotics). They were 
plated in 6-well plates and grown until they reached 30% confluency. siRNA was 
complexed with Oligofectamine (OFA, Invitrogen) according to the manufacturer’s 
recommendations or with CDP at a 3/1 (+/-) charge ratio. The resulting formulations were 
applied to each well in serum-free medium (OptiMEM) at a final siRNA concentration of 
100 nM for 4 h.  All transfected cells were harvested at 48 h, and EWS-Fli1 and β-actin 
protein levels were assessed by Western blot using primary monoclonal antibodies against 
the C-terminal region of Fli1 ( BD Biosciences) and polyclonal antibodies against β-Actin ( 
Santa Cruz Biotechnology). 
4.3.5 Preparation of formulations and injections of transgenic mice 
Transgenic C57BL/6 mice were prepared by pronuclear injection of a linearized 
pApoEHCRLuc plasmid (a generous gift of A. McCaffrey and M. Kay), which contains the 
firefly luciferase gene under the control of the human α1-antitrypsin promoter and the 
apolipoprotein E heterologous control region.  This plasmid restricts transgene expression 
to hepatocytes30.  All mice contained the luciferase gene (as confirmed by PCR analysis of 
tail cuts obtained when pups were 4 weeks old) and were 6 – 8  weeks of age at the time of 
the experiment.  Mice were treated according to the NIH Guidelines for Animal Care and 
as approved by the Caltech Institutional Animal Care and Use Committee.  All 
experimental manipulations with the mice were performed under sterile conditions in a 
laminar flow hood. 
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Polyplex formulations were prepared containing siGL3 or siCON1 and CDP (at a charge 
ratio of 3/1 +/-), 20% AD-PEG-Lac/80% Ad-PEG (w:w), and an overall 1:1 β-CD:AD 
(mol:mol).  One volume containing CDP, AD-PEG, and AD-PEG-Lac (in H2O) was added 
to an equal volume of siRNA (in H2O) to form polyplexes.  An equal volume of 10% (w:v) 
glucose (100 mg/mL glucose in H2O) was added to the polyplex solution to give a final 
polyplex solution in 5% glucose (D5W).  Formulations were administered by low-pressure 
tail vein (LPTV) injection; injection volumes were adjusted by mouse weight such that 
each 20-g mouse received 50 µg siRNA (2.5 mg/kg) in a volume of 200 µL (1% v:w).  
4.3.6 Determination of transferrin receptor (TfR) level of TC71 cells 
TC71, A2780 (American Type Culture Collection), and HeLa cells were analyzed for 
relative levels of transferrin receptor (TfR) expression. Cells were plated at 300,000/well in 
6-well plates 24 h before exposure to 1 mL of antibiotic-free culture medium containing 
1% BSA and various concentrations of fluorescein-labeled transferrin (Tf-FITC) (50, 100, 
or 250 nM) for 1 h at 37 oC as described previously27.  The cells were washed twice with 
phosphate-buffered saline (PBS), collected by trypsin treatment, washed twice in FACS 
buffer (25 mL of Hank’s Buffered Salt Solution supplemented with 2 mM MgCl2 and 10 
µL DNase) and resuspended in Hank’s Buffered Salt Solution for analysis by flow 
cytometry using a FACSCalibur (Becton Dickinson). 
4.3.7 Generation of luciferase-expressing TC71 (TC71-LUC) cells 
SMPU-R-MNCU3-LUC is a lentiviral vector based upon HIV-1 that transduces the 
firefly luciferase gene.  The backbone vector SMPU-R has deletions of the enhancers and 
promoters of the HIV-1 LTR (SIN), has minimal HIV-1 gag sequences, contains the 
cPPT/CTS sequence from HIV-1, has 3 copies of the UES polyadenylation enhancement 
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element from SV40, and a minimal HIV-1 RRE  (gift of Paula Cannon, Children’s 
Hospital-Los Angeles).  The vector has the U3 region from the MND retroviral vector as 
an internal promoter driving expression of the firefly luciferase gene from SP-LUC+ 
(Promega). TC71 cells were transduced with viral supernatant containing SMPU-R-
MNCU3-LUC vector31. A second cycle of transduction was performed 8 h later by 
removing old medium and adding new viral supernatant and medium. Twenty-four hours 
after the initial transduction, cells were thoroughly washed three times with PBS before in 
vitro analysis. 
4.3.8 Injection of NOD/scid mice with TC71-LUC cells 
TC71-LUC cells were cultured in RPMI 1640 medium with 10% fetal bovine serum (no 
antibiotics). To prepare for injection, cells were trypsinized from tissue culture flasks and 
washed twice with PBS. Cells were counted on a hemacytometer slide and resuspended 
in serum-free RPMI 1640 medium immediately prior to injection. The viability of the 
cells was tested by trypan blue exclusion; only cells more than 90% viable were used. 
Female NOD/scid mice were treated according to the NIH Guidelines for Animal Care 
and as approved by the Caltech Institutional Animal Care and Use Committee. All mice 
were 6-8 weeks of age at the time of injection. Each mouse was injected with 5 x 106 
TC71-LUC cells suspended in 0.2 mL RPMI 1640 (without FBS or antibiotics) through 
the tail vein using a 27-gauge needle. All experimental manipulations with the mice were 
performed under sterile conditions in a laminar flow hood. 
4.3.9 Bioluminescence imaging of mice 
Mice were imaged at indicated time points using an in vivo IVIS 100 
bioluminescence/optical imaging system (Xenogen). D-luciferin (Xenogen) dissolved in 
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PBS was injected intraperitoneally at a dose of 150 mg/kg (0.2 mL of a 15 mg/mL 
solution per 20-g mouse) 10 min before measurement of luminescence. General 
anesthesia was induced with 5% isoflurane and continued during the procedure with 
2.5% isoflurane introduced via a nose cone. 
After acquiring photographic images of each mouse, luminescent images were acquired 
with various (1 – 180 s) exposure times. The resulting grayscale photographic and 
pseudo-color luminescent images were automatically superimposed by the IVIS Living 
Image software (Xenogen) to facilitate the matching of the observed luciferase signal 
with its location within the mouse. Regions of Interest (ROI) were manually drawn 
around the bodies (NOD/scid) or abdominal regions (transgenic) of the mice to assess 
signal intensity emitted. Luminescent signal was integrated over these ROIs and is 
expressed as photons per second emitted. Tumor bioluminescence in mice has been 
shown to be linearly correlated with the tumor volume32-33, and we have verified these 
findings (data not shown).  For transgenic mice, fur in the abdominal region was removed 
by shaving once, prior to the start of the experiment, to permit detection of liver 
bioluminescence. 
4.3.10 Magnetic resonance imaging 
Before imaging, each mouse received 100 µL paramagnetic contrast agent MAGNEVIST 
(1 mL MAGNEVIST contains 469.01 mg gadopentate dimeglumine, 0.99 mg meglumine 
and 0.4 mg diethylentriamine pentaacetic acid) intraperitoneally to enhance delineation. 
Mice were sedated with 5% isoflurane and wrapped in cellophane to prevent hypothermia 
and minimize contamination of the MRI system. Isoflurane gas (0.8% in air) was used for 
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supplementary sedation as needed. All images were obtained using a BRUKER BIOSPIN 
MRI with a horizontal magnet of 7.0 Tesla (Bruker Instruments, Inc.). 
4.3.11 Preparation of formulations and injections of NOD/scid mice 
Polyplex formulations were prepared containing siGL3 or siCON1 and CDP at a charge 
ratio of 3/1 +/-. Prior to addition to siRNA, CDP was mixed with an adamantane-
(polyethylene glycol)5000 (AD-PEG) conjugate at a 1:1 AD:β-CD (mol:mol) ratio.  
Targeted polyplexes also contained transferrin-modified AD-PEG (AD-PEG-Tf) at a 
1:1000 AD-PEG-Tf:AD-PEG (w:w) ratio.  This mixture was then added to an equal 
volume of siRNA (in H2O) to form polyplexes.  An equal volume of 10% (w:v) glucose 
(100 mg/mL glucose in H2O) was added to the polyplex solution to give a final polyplex 
solution in 5% glucose (D5W) suitable for injection.  Formulations were administered by 
low-pressure tail vein (LPTV) injection using a 1-mL syringe and a 27-gauge needle; 
injection volumes were adjusted by mouse weight such that each 20-g mouse received 50 
µg siRNA (2.5 mg/kg) in a volume of 0.2 mL (1% v:w). 
Fifty female NOD/scid mice were injected with 5 x 106 TC71-LUC cells as described 
above. Immediately after cell injection, each mouse received an additional injection of 0.2 
mL of one of the following formulations (2.5 mg/kg siRNA, 10 mice per group): D5W 
only (group A); naked siEFBP2 only (group B); targeted, formulated siCON1 (group C); 
targeted, formulated siEFBP2 (group D); or non-targeted, formulated siEFBP2 (group E). 
Formulations were administered twice-weekly for four weeks. Images were taken 
immediately after the first injections for quality control of the injections and twice-weekly 
immediately before the injection of the formulations. We continued to monitor the tumor 
signal in the mice receiving targeted (group D) and non-targeted (group E) siEFBP2 
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formulations for an additional three weeks or until the tumor burden was too great for the 
mice. 
 4.3.12 Toxicity, immune response, and pathology studies 
Female C57BL/6 mice (Jackson Laboratories) were 6 – 8 weeks of age at the time they 
received a single injection of each of the five formulations listed above (six mice per 
group).  To measure plasma cytokine levels, blood was harvested from mice 2 h and 24 h 
post-injection (three mice per treatment for each timepoint) by cardiac puncture, and 
plasma was isolated using Microtainer tubes (Becton Dickinson). Whole blood was used 
for complete blood count (CBC) analyses, and plasma was used for all liver enzyme and 
cytokine analyses. IL-12 (p40) (BD Biosciences) and IFN-α levels (PBL Biomedical 
Laboratories) were measured by ELISA according to the manufacturer’s instructions. 
Major organs of the NOD/scid mice after long-term treatment studies were collected, 
formalin-fixed, and processed for routine hematoxylin and eosin staining using standard 
methods. Images were collected using a Nikon epifluorescent microscope with a DP11 
digital camera. 
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4.4 RESULTS 
 
4.4.1 siRNA-containing polyplexes down-regulate co-delivered luciferase in cultured 
cells 
 
An initial investgation of the ability of CDP/siRNA polyplexes to down-regulate a target 
gene was performed in HeLa (human cervical carinoma) and BHK (baby hamster kidney) 
cells, which have been previously shown to express genes delivered from CDP/pDNA 
polyplexes at high levels23.  Polyplexes were prepared that contained both a plasmid 
encoding the gene for luciferase (pGL3CV) alone, or with either an siRNA duplex 
targeting that luciferase gene (siGL3) or an siRNA duplex targeting an irrelevant gene 
(siEGFP).  Lipoplexes made with Lipofectin and the same combinations of nucleic acids 
were used as a positive control for down-regulation in HeLa cells.  Cells were exposed to 
polyplexes for 4 h and were lysed at 48 h post-transfection; the luciferase levels in lysates 
were measured by luminometer (Fig. 4.1). 
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Figure 4.1. CDP/siRNA down-regulates co-delivered luciferase in HeLa and BHK 
cells. (a) Lipoplexes or (b, c) polyplexes were prepared with CDP and pGL3CV alone or 
with either siGL3 or siEGFP.  Cells were exposed to polyplexes for 4 h and lysed 48 h 
post-transfection.  The luciferase levels in lysates are measured in relative light units 
(RLUs) and are normalized by the amount of protein in each sample.  Bars indicate 
averages of triplicate wells for each treatment, and error bars represent one standard 
deviation.  Sequence-specific down-regulation from siRNA-containing polyplexes is 
observed in both cell lines. 
 
Polyplexes containing a control siRNA sequence (siEGFP) show some, but non-zero, 
suppression of luciferase expression (42% and 35% reduction in HeLa and BHK cells, 
respectively, compared to CDP/pDNA only).  This non-specific down-regulation seen with 
siEGFP may be a consequence of the relative high dose (100 nM) of siRNA used here and 
has been reported elsewhere under similar conditions34-35.  By contrast, the amount of 
luciferase protein is reduced by 87% and 92% in HeLa and BHK cells, respectively, for 
siGL3-containing polyplexes.  These results are indicative of strong, sequence-specific 
luciferase suppression. 
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4.4.2 siRNA-containing polyplexes reduce expression of the EWS-Fli1 oncogene in 
cultured Ewing’s sarcoma cells 
 
Having demonstrated sequence-specific down-regulation of a co-delivered exogenous gene 
by CDP/siRNA complexes in cultured cells, the ability of these polyplexes to reduce levels 
of an endogenous gene was examined in cultured Ewing’s sarcoma (TC71) cells.  siRNA 
duplexes were obtained that either target the junction of the EWS-Fli1 fusion gene 
(siEFBP2) or a mutated, non-functional variant (siEFBP2mut).  Lipoplexes were made 
with Oligofectamine, a commercially available lipid reagent, as a positive control for 
down-regulation.  EWS-Fli1 protein levels were measured in the lysates of cells 48 h after 
transfection by Western blotting (Fig. 4.2).    
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Figure 4.2. CDP/siRNA down-regulates oncogenic EWS/Fli-1 in cultured Ewing’s 
sarcoma cells. Lipoplexes made with Oligofectamine (OFA) or polyplexes made with 
cyclodextrin-containing polycation (CDP) and siRNA targeting the breakpoint of the EWS-
Fli1 fusion gene (siEFBP2) or a mutated, non-functional siRNA (siEFBP2mut) were 
prepared; cultured TC71 Ewing’s sarcoma cells were exposed to these complexes for 4 h 
and lysed 48 h post-transfection.  (a) The EWS-Fli1 protein levels were measured by 
Western blot and compared to those of β-actin.  (b) Quantification of the Western blot; 
values presented are the ratio of EWS-Fli1 to β-actin band intensities as determined by 
densitometry. 
 
Using a previously reported siRNA sequence targeting the EWS-FLI1 breakpoint 
(siEFBP2)29, we observed comparable and significant (greater than 50%) reduction in 
EWS-FLI1 protein levels using both Oligofectamine and CDP.  Delivery of a mutated 
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siRNA sequence (siEFBP2mut) failed to elicit such down-regulation (data not shown for 
CDP), demonstrating the sequence-specific nature of the RNAi effect. 
 
4.4.3 Galactosylated polyplexes down-regulate hepatic luciferase in transgenic mice 
 
After successful demonstration of down-regulation of both endogenous and exogenous 
targets in cultured cells, siRNA-containing polyplex formulations were then tested for their 
ability to achieve similar down-regulation in vivo.  Transgenic C57BL/6 mice were created 
that constitutively express luciferase exclusively in hepatocytes within their livers.  
Hepatocytes express high levels of the cell surface asialoglycoprotein receptor (ASGPr), 
which is known to recognize galactose as a ligand36-37.  External material that is 
galactosylated and sufficiently small (less than ~70 nm in diameter38) may be endocytosed 
by hepatocytes.  Thus, CDP/siRNA polyplexes were targeted to hepatocytes by 
galactosylation via incorporation with an AD-PEG-Lactose modifier (galactose is the 
terminal moiety of lactose, a disaccharide). 
Luciferase-expressing mice received three consecutive daily administrations of 
galactosylated CDP/siRNA polyplexes containing either siRNA targeting luciferase 
(siGL3) or a single injection of polyplexes containing non-targeting control sequence 
(siCON1) followed by two consecutive daily administrations of carrier solution only 
(D5W).  The hepatic luciferase signal in these mice was monitored and quantified by 
whole-animal in vivo bioluminescent imaging and is presented in Figure 4.3.   
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Figure 4.3. Galactosylated CDP/siRNA down-regulates luciferase in livers of 
transgenic mice. Polyplexes were prepared with CDP, siRNA against luciferase (siGL3) 
or a non-targeting control sequence (siCON1), and AD-PEG-Lac to target hepatocytes.  
Transgenic mice bearing hepatocyte-specific luciferase expression received three 
consecutive daily injections of siGL3-containing formulations by LPTV on Days 0, 1, and 
2.  Control mice received one injection of the siCON1-containing formulation followed by 
two consecutive daily injections of carrier solution (D5W).  (a) The timecourse of 
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luciferase expression was followed and quantified by whole-animal bioluminescent 
imaging.  Integrated signal is presented as a percentage of the signal on Day –2 (for each 
mouse).  Error bars represent one standard deviation from the mean. (b) Images of one 
mouse from each group are shown from Days –2, 7, and 19 post-injection. Mice receiving 
the siGL3-containing formulation show significant luciferase down-regulation (up to 
>50%) that was maximal at Day 7. 
 
Down-regulation of luciferase was observed for mice receiving galactosylated siGL3-
containing formulations.  Luciferase reduction was most significant between days 4 and 9 
after the first injection, with a maximal reduction of 75% seen on day 7.  Significant 
reduction was not seen for mice receiving the control injections at any timepoint examined.  
These results indicate that CDP/siRNA polyplexes targeted with AD-PEG-Lac are suitable 
for uptake and down-regulation of a target gene in hepatocytes.  
 
4.4.4 Transferrin-targeted polyplexes inhibit Ewing’s sarcoma tumor formation in 
mice 
 
It was shown previously that CDP/siRNA polyplexes are capable of reducing levels of the 
EWS-Fli1 fusion oncogene in cultured Ewing’s sarcoma cells (see Section 4.4.2).  Given 
this result and the in vivo knockdown targeting polyplexes produced in transgenic mice 
expressing luciferase in hepatocytes (see Section 4.4.3), it was hypothesized that 
polyplexes targeted to Ewing’s sarcoma cells could be employed to inhibit Ewing’s 
sarcoma tumorigenesis in mice. 
In order to examine this possibility, a target on the cell surface of Ewing’s sarcoma cells 
needed to be identified.  Since the membrane-bound transferrin receptor (TfR) has been 
shown to be up-regulated in a wide variety of cancers39, we assessed the level of TfR on 
cultured TC71 Ewing’s sarcoma cells.  The uptake of fluorescein-labeled transferrin (Tf-
FITC) by TC71 cells was measured by flow cytometry and compared to that of cell lines 
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known to express very high (HeLa) and low (A2780) levels of TfR; the results are shown 
in Figure 4.4. 
 
Figure 4.4. TC71 Ewing’s sarcoma cells display high levels of transferrin receptor 
(TfR). Cultured TC71, HeLa, and A2780 cells were each exposed to three different Tf-
FITC concentrations (50, 100, and 250 nM) for 1 h at 37 oC.  The fluorescence levels of 
cells were then measured by flow cytometry.  Like HeLa cells, TC71 cells displayed strong 
fluorescence at all three Tf-FITC concentrations examined.  This suggests that TC71 cells 
express large numbers of TfR molecules on their surface and that TfR may be an 
appropriate candidate for targeting of polyplexes to TC71 cells in vivo. 
 
Because the fluorescence of TC71 cells exposed to all three concentrations of Tf-FITC was 
very high (>80% compared to untreated control cells), we conclude that TfR levels on 
TC71 cells are high enough to consider targeting polyplexes to TfR to direct uptake by 
TC71 cells in vivo.  Further, analogous to the targeting of ASGPr on hepatocytes with an 
adamantane-poly(ethylene glycol)-lactose (AD-PEG-Lac) conjugate discussed above (see 
Section 4.3.3), the synthesis and characterization of an AD-PEG-Tf conjugate, and its use 
to target TfR-expressing cells, have previously been described26. 
TC71 cells were made to constitutively express luciferase (TC71-LUC cells) via lentiviral 
infection such that tumor formation could be followed by whole-animal bioluminescence 
imaging.  In order to determine our ability to follow these cells by imaging and the extent 
of tumorigenesis, NOD/scid mice were injected with TC71-LUC cells by tail vein 
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injection.  The mice were monitored by imaging, and selected tumor-bearing mice were 
additionally examined by magnetic resonance imaging (MRI).  Representative images are 
shown in Figure 4.5. 
 
Figure 4.5. Establishment of a disseminated Ewing’s sarcoma model in mice. 
(a) NOD/scid mice injected with TC71-LUC cells developed metastatic tumors. Mice were 
injected with TC71-LUC cells via the tail vein. At various time points after injection, mice 
were anesthetized, injected with D-Luciferin, and imaged using a Xenogen IVIS 100 
bioluminescence imaging system. (b) MRI confirmation of EFT engraftments. Tumor-
bearing mice were anesthetized, injected with contrast agent, and imaged. Tumor locations 
observed by MRI corresponded to bioluminescent signal. 
 
After initially residing in the lung capillary beds, injected TC71-LUC cells disseminated, 
and tumors were visualized in a variety of locations a couple of weeks after injection.  
Overall, the tumor engraftment sites observed (lung, vertebral column, pelvis, femur, and 
soft tissue) were comparable to the most common locations of metastases in EFT patients. 
The ability of targeted, siRNA-containing polyplexes to down-regulate EWS-Fli1 in these 
TC71-LUC-derived tumors was then tested, both indirectly by bioluminescence imaging 
and directly by qRT-PCR analysis of harvested tumors.  Mice that had formed tumors after 
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injection with TC71-LUC cells were treated with two consecutive daily injections of 
polyplexes that were targeted with AD-PEG-Lac and contained siRNA targeting the 
EWS/Fli1 fusion gene (siEFBP2).  A summary plot of the imaging results is shown in 
Figure 4.6. 
 
Figure 4.6. Targeted polyplexes containing siRNA against EWS-Fli1 reduced tumor 
bioluminescence in mice. siRNA against EWS-Fli1 (siEFBP2) was formulated with CDP 
and targeted with Ad-PEG-Tf.  Two tumor-bearing mice received this formulation by low-
pressure tail vein (LPTV) injection on three consecutive days (Days 35, 36, and 37; red 
arrows) after injection of TC71-LUC cells. Tumor size was quantified by integration of 
bioluminescent flux (photons/sec) at indicated timepoints.  Transient reduction in 
bioluminescence was observed on days 36 and 37. 
 
We hypothesized that targeted siEFBP2-containing polyplexes would reduce the rate of 
tumor growth in mice receiving them, leading to a transient reduction in the rate of 
increase, or even a decrease, of tumor bioluminescence.  Indeed, a transient reduction in 
bioluminescence was seen on days 1 and 2 after the first of consecutive daily injections of 
these formulations.  While indirect, this result suggested that the expected knockdown of 
the EWS/Fli1 gene in TC71-LUC cells in vivo was occurring. 
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To probe this down-regulation more directly, similar (two consecutive daily) injections 
were made in tumor-bearing mice of targeted polyplexes containing either siEFBP2 or a 
non-targeting control sequence (siCON1).  This time, instead of simply following the 
bioluminescence, mice were sacrificed the day after the second injection, tumors were 
harvested, and the levels of EWS/Fli-1 mRNA transcripts were measured by quantitative, 
real-time PCR (qRT-PCR).  The results are shown in Figure 4.7. 
 
Figure 4.7. Targeted polyplexes containing siEFBP2 reduced EWS-Fli1 mRNA levels 
in tumors. Formulated siEFBP2 or siCON1 were administered by LPTV injection on two 
consecutive days in tumor-bearing (TC71-LUC) NOD/scid. Tumors were harvested on the 
day after the second injection, RNA was extracted from these tumors, and EWS-FLI1 
mRNA levels were determined by qRT-PCR (relative to a β-actin control).  The mean of 
three measurements is presented; error bars represent standard deviation. 
 
Two consecutive daily injections of Tf-targeted, siEFBP2-containing formulations  reduced 
EWS-Fli1 transcript levels by greater than 50% compared to formulations made with a 
control siRNA sequence (siCON1).  Taken together with the results of Figure 4.6, this 
provides both indirect and direct evidence that formulated siRNA can achieve the desired 
gene knockdown in vivo. 
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The final hypothesis that was examined regarding these formulations was whether or not 
this target gene knockdown in vivo would have a corresponding therapeutic effect, e.g., 
reduced tumor growth.  In order to answer this, a long-term treatment schedule was 
adopted in which TC71-LUC-treated mice received twice weekly injections of 
formulations for four weeks, starting immediately after injection of TC71-LUC cells (see 
Table 4.1).  Five different treatment groups, containing ten mice each, were established. 
Group ID Mouse IDs Treatment 
A #1-10 carrier solution (D5W) 
B #11-20 naked siEFBP2 
C #21-30 targeted, formulated siCON1 
D #31-40 targeted, formulated siEFBP2 
E #41-50 non-targeted, formulated siEFBP2 
Table 4.1. Treatment groups for long-term tumor inhibition study. 
 
Tumor growth was monitored and quantified by whole-animal bioluminescence imaging; a 
summary plot of the results is shown in Figure 4.8 (see Appendix for all images). 
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Figure 4.8. Targeted polyplexes containing siEFBP2 reduced tumor growth levels in 
mice. Starting immediately after injection of TC71-LUC cells, mice were treated with 
formulations containing siRNA targeting EWS-FLI1 (siEFBP2) or a non-targeting control 
sequence (siCON1) by LPTV injection twice-weekly for four weeks. The bioluminescence 
of these mice was monitored twice-weekly. The median integrated tumor bioluminescent 
signal (photons/sec) for each treatment group [n=8-10] is plotted versus time after cell 
injection (days). [Treatment groups: A, 5% (w/v) glucose only (D5W); B, naked siEFBP2; 
C, targeted, formulated siCON1; D, targeted, formulated siEFBP2; E, non-targeted, 
formulated siEFBP2.] 
 
These long-term (four weeks) injections of siRNA-containing formulations in tumor-
bearing NOD/scid mice reveal that only the targeted, formulated siEFBP2 achieves long-
term tumor growth inhibition.  Neither naked siEFBP2 nor a formulated control siRNA 
sequence shows any effect on tumor signal compared to the control group receiving only 
the carrier fluid. These results demonstrate the sequence-specificity of the observed 
inhibition, the necessity of the targeting agent (AD-PEG-Tf), and the therapeutic potential 
of this delivery system. 
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Finally, the safety and immunogenicity of these five formulations were examined.  Acute 
effects were examined after single administrations of each of these formulations in 
C57BL/6 (non-transgenic) mice.  Whole blood and plasma were isolated at both 2 h and 24 
h post-injection.  Complete blood counts (CBCs) were determined from whole blood 
samples, while the levels of a number of secreted proteins associated with liver function, as 
well as two cytokines indicative of an immune response (interleukin-12 (IL-12) and 
interferon-alpha (IFN-α)), were measured in plasma samples.  To investigate chronic 
toxicity, major organs (liver, lung, heart, kidney, and spleen) were isolated from a mouse in 
each of three treatment groups, sectioned, subjected to hematoxylin and eosin staining, and 
examined.  All results are shown in Figure 4.9. 
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Figure 4.9. Formulated siRNA failed to exhibit toxicity or elicit an immune response 
in mice. CBC and liver panel results for C57BL/6 mice receiving formulations showed 
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no toxicity or immune response. Female C57BL/6 mice received a single administration 
of formulated siRNA. At 2 h or 24 h post-treatment, blood was drawn by cardiac 
puncture and plasma was isolated. (a,b) Whole blood was used for determination of 
platelet (PLT) and white blood cell (WBC) counts. Plasma was used for measurement of 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase 
(ALKP), creatinine (CRE), and blood urea nitrogen (BUN). The averages of triplicate 
mice for each time point are plotted; error bars represent standard deviations. (c,d) 
Cytokine ELISA results for C57BL/6 mice receiving formulations showed no up-
regulation of IL-12 or IFN-α. The plasma levels of interleukin-12 (IL-12 (p40)) and 
interferon-alpha (IFN-α) in mice described above were measured by ELISA. [Treatment 
groups: A, 5% (w/v) glucose only (D5W); B, naked siEFBP2; C, targeted, formulated 
siCON1; D, targeted, formulated siEFBP2; E, non-targeted, formulated siEFBP2; Wild-
type, uninjected; 2, blood drawn 2 h after injection; 24, blood drawn 24 h after injection.] 
(e) H&E staining of major organs of the NOD/scid mice after long-term treatment. Major 
organs were collected, formalin-fixed, and processed for routine hematoxylin and eosin 
staining using standard methods. Images were collected using a Nikon epifluorescent 
microscope with a DP11 digital camera. 
 
Collectively, none of the formulations show any significant effects on the levels of IL-12, 
IFN-α, white blood cells, platelets, secreted liver enzymes (ALT and AST), BUN, or CRE 
in immunocompetent (C57BL/6), and histology of the major organs of mice receiving 
long-term treatment (twice-weekly injections for four weeks) showed no apparent damage. 
These results show the safety and low immunogenicity of CDP-containing formulations 
and demonstrate the attractiveness of this methodology for systemic, targeted delivery of 
nucleic acids. 
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4.5 DISCUSSION 
 
Galactosylated CDP/siRNA formulations elicited down-regulaton of luciferase within 
hepatocytes of transgenic mice.  Since galactose is the ligand recognized by 
asialoglycoprotein receptor (ASGPr) on the surface of hepatocytes, our first investigations 
with targeting of (DNA-containing) polyplexes to hepatocytes involved synthesis of AD-
PEG-galactose (as opposed to AD-PEG-lactose used here).  However, our modification at 
galactose at the C2 moiety had been shown by others to be inferior to modification at the 
C1 moiety40 in terms of uptake by hepatoma cells.  Because synthesis of an alternative AD-
PEG-galactose modified at C1 proved difficult, we instead developed the AD-PEG-lactose 
conjugate used here28.  While a 20% AD-PEG-Lac/80% AD-PEG mixture appears here to 
be adequate to achieve down-regulation of a liver target gene, more work is warranted to 
determine the amount of AD-PEG-Lac necessary for targeting and to quantify the amount 
of Ad-PEG-Lac incorporated within the polyplexes (vs. unbound).  These subjects will be 
discussed in more detail in Chapter 5.  Also, we attribute the relatively noisy (large error 
bars) liver luciferase data to the relatively low absolute levels of bioluminescence from 
these transgenic mice (compared to what we typically observe after HPTV injection of the 
pApoEHCRLuc plasmid). 
We observe that the kinetics of luciferase down-regulation in transgenic mice are 
significantly slower than those of EWS/Fli1 knockdown in Ewing’s sarcoma cells within 
NOD/scid mice.  Indeed, the maximum knockdown in liver-specific luciferase expression 
was seen seven days after the first of three consecutive injections; in contrast, the biggest 
reduction in luciferase signal (an indirect measure of EWS/Fli1 knockdown) in TC71-LUC 
cells was seen just two days after the first of two consecutive treatments.  We attribute this 
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difference to the drastic difference in cell proliferation rates between mainly stationary 
hepatocytes and actively dividing TC71-LUC cells.  It is also worth noting that the 
timecourse of liver luciferase knockdown seen here (~1-2 weeks) is comparable to that 
seen after HPTV co-injection of a luciferase-bearing plasmid and siRNA targeting 
luciferase (see Chapter 2). 
 
While our method of long-term treatment will not translate directly to therapeutic treatment 
of cancer in humans (administration of formulations was begun the same day as injection 
of the TC71-LUC cells), we are encouraged at the significant inhibition of tumor growth 
observed using Tf-targeted, siEFBP2-containing polyplexes.  This inhibition persisted even 
well after the final treatment was administered.  This observation speaks well to the 
potency of these duplexes to prevent tumor engraftment, and future exploration as part of a 
combination therapy with more traditional chemotherapeutics is warranted.  Also, while the 
effect of Tf-targeting is clear (non-targeted siEFBP2-containing formulations fail to 
significantly inhibit tumor growth), the extent of targeting, and whether or not this could be 
improved upon, still remains unmeasured.  While we demonstrated that TfR is expressed at 
high levels (up-regulated) on TC71-LUC cells, it is possible that basal levels of TfR on 
other cell types are enough to significantly reduce the fraction of polyplexes that reach 
TC71-LUC cells.  If this is true, one should consider using a more cell type-specific target 
(such as CD99 for Ewing’s sarcoma cells) to increase the “effective dose” of polyplexes 
that are taken up by the desired target cells. 
The siCON1 duplex contains a sequence of bases, 5’-UGUGU-3’, that has been recognized 
as a putative immunostimulatory motif 21.  When encapsulated in lipids and administered to 
immunocompetent mice, multiple siRNA duplexes containing this motif were shown to 
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significantly increase IFN-a levels and reduce numbers of platelets and white blood cells21.  
In this investigation, targeted CDP/siCON1 polyplexes did not produce any of these effects 
in immunocompetent C57BL/6 mice.  This observation leaves open the possibility that the 
sequence-specific immunogenicity reported elsewhere may be due, at least in part, to the 
character of the liposomal delivery system.  Given the extreme hydrophilicity of all of the 
components of the polymeric delivery system examined here, one hypothesis for the 
difference in results with the two delivery systems lies in the hydrophilicity of all of the 
components of the polymeric delivery system examined here versus the relatively 
hydrophobic nature of the liposomes.  It seems possible that, within the bloodstream of 
recipient mice, liposomes may be more likely to partition to peripheral blood mononuclear 
cells (PBMCs), the cells which have been implicated in the observed responses21. 
Overall, the results of Chapter 4 demonstrate the safety and efficacy of systemically-
administered, targeted, siRNA-containing polyplexes in vivo.  These observations suggest 
that development of non-viral siRNA delivery systems for human therapeutic applications 
is indeed possible and, given the tremendous potency of RNAi in general (especially 
compared to previous-generation molecular therapeutics, such as antisense) and seen here, 
should be explored in the near future. 
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CHAPTER 5: Recommendations 
 
5.1 ABSTRACT 
The results shown in the previous three chapters demonstrate the safety of siRNA duplexes 
for use as therapeutics, their successful formulation within a polymer-based delivery 
system, and the efficacy of these small interfering RNA-(siRNA-)containing formulations 
to achieve targeted gene down-regulation in vivo.   Despite these successes, the room for 
further formulation development for even greater potency is large.  In this chapter, some 
ideas and experiments for better understanding of current formulations and modifications 
for improvement of these formulations are discussed.  The importance of and methods for 
quantification of both the siRNA payload and the amount of targeting ligand incorporated 
in each polyplex are investigated.  I also discuss the prospect of using alternative targeting 
ligands with greater binding affinity and/or higher relative up-regulation on target cells.  
Finally, recent literature results suggest that alternative dsRNA duplexes can be more 
potent RNA interference (RNAi) effector molecules than the 21-nt siRNAs used here; these 
will be discussed.  All of these issues warrant continued development towards production 
of an optimized formulation for therapeutic RNAi.
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5.2 RECOMMENDED FUTURE DIRECTIONS 
5.2.1 Quantification of siRNA payload 
The characterization of polyplexes made with a cyclodextrin-containing polycation (CDP) 
and small interfering RNA (siRNA) duplexes detailed in Chapter 3 demonstrates the 
complete condensation of siRNA within all formulations having a positive (i.e., greater 
than 1/1 (+/-)) charge ratio.  Indeed, it was shown that for all polyplexes prepared at an 
overall positive charge ratio, the amount of CDP actually within polyplexes was only 
enough to balance the negative charges on the siRNA; all additional polymer remained 
unbound.  Knowing this information, further determination of the polyplex average molar 
mass would allow calculation of the average number of CDP and siRNA molecules per 
polyplex. 
The molar mass of a polyplex solution can be determined via multi-angle laser light 
scattering (MALLS).  An extension of the single-angle dynamic light scattering (DLS) used 
to assess polyplex size in Chapter 3, detectors are employed to measure the light scattered 
from a polyplex sample at seventeen different angles.  From light scattering theory, 
extrapolation of scattering intensity to zero-angle (0 oC), along with knowledge of the 
polyplex solution mass concentration and index of refraction, can be used to determine 
both the polyplex average hydrodynamic radius and the average molar mass1. 
Armed with polyplex molar mass information, the average number of polymer and nucleic 
acid molecules per polyplex can be calculated using the system of two equations with two 
unknowns shown in Figure 5.1. 
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Figure 5.1. Calculation of average polyplex stoichiometry. The average number of 
polymer and nucleic acid molecules per polyplex can be calculated from the “effective 
polyplex charge ratio” (EPCR, described in Chapter 3) and the polyplex molar mass.  
Example values for CDP (two positive charges per repeat unit, repeat unit MW = 1460) and 
pDNA (5256 bp) are: A = 14, B = 10512, MWCDP = 10,000 (Da), and MWpDNA = 3.5 x 106 
(Da). 
 
Indeed, MALLS has been employed previously with CDP/pDNA polyplexes in order to 
determine molar mass and polyplex stoichiometry2.  The average polyplex molar mass was 
determined to be ~1 x 107 Da, from which the average number of polymer and pDNA 
molecules per polyplex were calculated to be 1200 and 1.7, respectively.  This was an 
important finding because it indicated that the number of plasmids, and therefore the 
number of genes, in an individual complex is very small (1 or 2).  It also sheds light on the 
range of target ligand densities that are possible, as will be discussed in further detail 
below. 
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I recommend that MALLS be applied to CDP/siRNA polyplexes as well to determine what 
the number of siRNA molecules per polyplex is and how that number compares to what 
has been found previously for pDNA.  Given the results of Chapter 3 that show nearly 
identical relationships between polyplex size and concentration for pDNA- and siRNA-
containing formulations, under both unPEGylated and PEGylated conditions, it seems 
reasonable to hypothesize that the total masses of siRNA and pDNA within their respective 
individual polyplexes are also similar.  If that is true, then, owing to the ~100-fold smaller 
molecular weight of siRNA compared to pDNA, we might expect to find ~170 siRNA 
molecules per polyplex.  Such a result would suggest that CDP-containing polyplexes hold 
the potential to be much more effective at delivering siRNA for RNAi than at delivering 
pDNA for gene therapy, if only because the per-polyplex, per-molecule payload is much 
greater for siRNA-containing complexes.  But this remains only a hypothesis until MALS 
analysis of CDP/siRNA polyplexes and subsequent stoichiometry calculations are 
performed. 
 
5.2.2 Quantification of ligand density 
In Chapter 4, the in vivo efficacy of CDP/siRNA polyplexes containing two different 
targeting ligands is shown.   Lactose-containing polyplexes achieved luciferase down-
regulation in the livers of recipient mice, while transferrin-containing complexes knocked 
down levels of the chimeric EWS-Fli1 oncogene in tumors (Ewing’s sarcoma).  These 
ligands were selected for targeting of asialoglycoprotein receptor- (ASGPr-)rich 
hepatocytes and transferrin receptor- (TfR)-rich tumor cells, respectively.  While both of 
these ligands were incorporated into polyplexes in the same way (via tethering to 
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adamantane-poly(ethylene glycol) (AD-PEG) conjugates), the size and nature of these 
ligands are very different (lactose is a relatively small disaccharide, while transferrin is a 
comparatively large protein). 
Based on some preliminary in vitro work and successful results published elsewhere3-5, we 
employed 0.1% (1:1000 w:w) AD-PEG-Tf/AD-PEG and 20% (1:5 w:w) AD-PEG-
Lac:AD-PEG loadings, respectively.  While these are the total amounts added to the 
formulation, this is certainly not reflective of the exact amount of these AD-PEG-ligand 
species within the polyplexes themselves.  For example, at 3/1 (+/-) formulation conditions, 
two-thirds of all CDP molecules remain unbound, and thus AD-PEG-ligand molecules that 
have formed inclusion complexes with these unbound CDPs will not contribute to polyplex 
target.  If anything, they have the potential to reduce polyplex targeting by competing with 
ligands on the polyplexes for cell surface receptors. 
The recommendation here is that the incorporation of these ligands within polyplexes be 
further quantified.  Essential to such quantification is the ability to separate unbound 
material from polyplexes, a method for which I have developed using a centrifugal 
filtration unit (illustrated schematically in Fig. 5.2). 
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Figure 5.2. Centrifugal filtration to separate unbound material from polyplex 
formulations.  As-prepared polyplex formulations are placed in a centrifugal filtration unit 
consisting of a reservoir above a membrane having a specified molecular weight cut-off 
(MWCO, typically 50,000 Da).  Centrifugation drives solution containing unbound species 
(e.g., CDP, AD-PEG, and AD-PEG-Lac) through the filter while retaining polyplexes that 
are too large to pass through it.  
 
Preliminary work with this separation strategy using CDP/pDNA polyplexes has 
demonstrated that (1) polyplexes must be PEGylated in order to avoid sticking to the 
membrane, (2) all polyplexes are retained in the sample reservoir upon centrifugation, and 
(3) the effective diameter and count rate of polyplexes are unchanged after centrifugal 
filtration (data not shown). 
Centrifugal filtration to remove unbound materials within formulations could be used to 
quantify polyplex ligand density in multiple ways.  For AD-PEG-Lac-containing 
formulations, separation of free material using a MWCO = 50,000 Da could be followed by 
direct quantification of galactose using a standard, commercially-available galactose 
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oxidase assay (described in 6).  Indirect assessment of galactose density could also be 
performed using an in vitro lectin (RCA120) agglutination assay6.  Membranes having a 
larger MWCO would be required for AD-PEG-Tf-containing formulations due to the 
relatively large size (MW ~80,000 Da) of transferrin.  The amount of Tf within filtered 
polyplexes could easily be determined by a standard protein detection assay (e.g., DC 
Protein Assay, Bio-Rad).  Additionally, if fluorophore-containing species of each of these 
conjugates were prepared (e.g., AD-PEG-FITC-Lac or AD-PEG-FITC-Tf), quantification 
of ligand density could be performed simply by measurement of fluorescence. 
 
5.2.3 Alternative ligands for improved targeting  
While the targeting ligands employed here appeared sufficient to generate target gene 
knockdown from siRNA-containing polyplexes, it is very possible that improvements in 
ligand selection and/or design could provide significant improvement of the overall 
formulation potency. 
The monovalent galactose moieities presented here (via AD-PEG-Lactose) are an 
improvement upon our initial attempts to target hepatocytes but, based on the work of other 
experimenters, could be greatly improved upon to reach ASGPr-expressing hepatocytes.  
Initial efforts to target CDP/pDNA polyplexes to hepatocytes were made using AD-PEG-
Galactose, as galactose itself is the ligand recognized by ASGPr.  However, this 
conjugation scheme, which involved forming a bond between galactosamine and the 
adamantane modifier via the C2 position on the sugar5, was found by others to be inferior 
for hepatoma cell uptake to modification at the C1 position7.  This obstacle was overcome 
by employing a different synthetic scheme that incorporated lactose, instead of galactose, 
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into the AD-PEG-conjugate8.  However, there is abundant literature suggesting that 
multiantennary presentation of galactose, as well as different galactose derivatives (e.g., N-
acetylgalactosamine (GalNAc)) having significantly enhanced binding affinity for ASGPr, 
could lead to improved specificity of targeted polyplexes9-11.  This issue of binding affinity 
is particularly important given the relatively few ligand incorporation sites (β-CD moieties 
within bound CDP molecules) within our polyplexes.  The use of stronger binding 
galactose derivatives should be considered to confer enhanced polyplex targeting to 
hepatocytes. 
Because the transferrin receptor (TfR) has been shown to be up-regulated in actively 
dividing cells12, including cancer cells13 such as Ewing’s sarcoma14, we employed 
conjugates of AD-PEG containing iron-loaded transferrin (AD-PEG-Tf) to target Ewing’s 
sarcoma (ES) cells.  Because all non-cancerous cells have non-zero levels of TfR on their 
surfaces, however, the possibility of receptor-mediated endocytosis of targeted polyplexes 
by undesired cell types remains.  A ligand/receptor combination that would be more 
specific to ES cells, if it exists, would be likely to confer even better targeting of 
formulations to these cells.  Literature results indicate that the cell surface molecule CD99, 
which is over-expressed on Ewing’s family of tumors only, may be one such target15.  In 
addition to enhanced specificity, engagement of CD99 has been shown to have a functional 
role in inducing apoptosis16.  Anti-CD99 antibodies (or antibody fragments) should be 
considered for incorporation within AD-PEG-conjugates to generate formulations of which 
an even higher fraction of the administered dose reaches these target ES tumor cells.   
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5.2.4 Alternative dsRNA duplexes for improved potency 
A final point to consider in order to improve potency of these formulations is the nature of 
the therapeutic agent (siRNA duplex) itself.  Very recently, it has been reported that 
synthetic dsRNA molecules that are somewhat longer than siRNA duplexes (~25-30 nt in 
length) can be up to two orders of magnitude more potent than corresponding siRNAs17.  In 
the discussion of the mechanism of RNAi in Chapter 1, it was mentioned that siRNA 
duplexes bypass the initial Dicer-mediated cleavage event normally performed on longer 
dsRNAs to generate the siRNA effector duplexes that are recruited to RISC.  These new 
results support a new hypothesis that these longer dsRNAs, which are Dicer substrates, are 
more potent because of the coupled nature of the production of siRNA and its incorporation 
within RISC.  Indeed, a separate report indicates that synthetic, 29-bp small hairpins RNAs 
(shRNAs) are also more potent than corresponding siRNAs and describes the precise 
nature of Dicer shRNA cleavage products18.  Both of these studies demonstrate that, if 
properly designed, longer dsRNAs can be much stronger down-regulators of a given target 
gene.  I recommend that such dsRNAs be explored for subsequent applications of these 
targeted non-viral formulations. 
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APPENDIX 
 
Images of NOD/scid mice injected with TC71-LUC cells and treated twice-weekly with 
various formulations. 
 
Images correspond to the following time points: 
 
 Immediately after injection of cells (pg. 123) 
 2 weeks post-injection (pg. 124) 
 2.5 weeks post-injection (pg. 125) 
 3 weeks post-injection (pg. 126) 
 3.5 weeks post-injection (pg. 127) 
 4 weeks post-injection (pg. 128) 
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